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Abstract
Investigating tumour micro environment dynamics based on
cytokine-mediated innate-adaptive immunity
Innocenter Moraa Amima
Thesis: MSc. (Mathematics)
March 2018
Cancer is a leading cause of death worldwide, yet much is still unknown about its mech-
anism of establishment, recurrence cycle and destruction. It is known that the succes-
sive alterations that occur in a set of specific genes in the cell can trigger carcinogenesis
which is the process of transforming a normal cell into a cancer cell. This process is
usually done in the following three steps: initiation, proliferation and progression. Can-
cer stem cells are regulated by complex interactions with the components of the tumour
micro-environment (TME) through networks of cytokines and growth factors. Thus, un-
derstanding the role of cytokines can be crucial in the fight against cancer in the context
of improving diagnostic, prognostic and therapeutic strategies. Several studies have in-
vestigated tumour-immune cell dynamics. However, some of these studies are mostly
limited to cells that directly kill cancer cells, such as natural killer (NK) and cytotoxic T
lymphocytes (CTLs), and they do not explicitly integrate cytokines in the cell dynamics.
Furthermore, none of these studies has combined cellular-level mathematical models
with molecular-level/signalling pathway analysis, to predict biological processes and
enriched pathways associated in cancer disease.
In this study, a new non-linear mathematical model integrating cytokines in the activa-
ii
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tion of innate and adaptive immunity was developed to predict the role of cytokines
in tumour and immune cell dynamics. Our work complements the role Th2 and Th17
cells play in inhibiting the proliferation of M1 macrophages, CTLs, NK and Th1 cells.
Numerical analysis of the model suggested that, lack of TGF-β inhibition effect resulted
in tumour clearance, however, the immune cells grew without bound and exceeded the
carrying capacity of immune cells. TGF-β is responsible for promoting tumour progres-
sion, tumour proliferation and limiting the effectiveness of type 1 immune response. In
addition, we established the necessary conditions for tumour clearance by varying pa-
rameter values. For an immune (effector) cell to be activated from a resting state, its gene
expression must be altered. We used datasets from The Cancer Genome Atlas (TCGA)
and an expression level-based model to identify genes specific to cancer patients con-
tributing to the regulation of cytokines in the context of the breast cancer disease. We
predicted differentially expressed genes (DEGs) associated with breast cancer disease
using a permutation-based significance analysis of micro-array (SAM) approach. Using
a selected list of the DEGs, we determined significant pathways and enriched biological
processes associated with breast cancer disease. Some of the identified significant bio-
logical pathways and processes, happened to be associated with cell differentiation or
cell division and the predicted over-expressed genes in tumour samples may contribute
to the proliferation of cancer. These genes, pathways and biological processes can be
further assessed to check for their suitability as targets for breast cancer disease.
Keywords: Tumour cells, immune cells, cytokines, differentially expressed genes.
Stellenbosch University  https://scholar.sun.ac.za
Opsomming
Ondersoek van die mikro-dinamika van die tumor mikro-omgewing,
gebaseer op sitokien-gemedieerde aangebore-adaptiewe immuniteit
( Investigating tumour micro environment dynamics based on cytokine-mediated innate-adaptive
immunity )
Innocenter Moraa Amima
Tesis: MSc. (Wiskunde)
Maart 2018
Kanker is wereldwyd een van van die grootste oorsake van dood en steeds is daar nog
baie onbekend oor die meganisme van onstaan, herverskynings siklus en vernietiging.
Dit is bekend dat die opeenvolgende veranderinge wat in ’n stel spesifieke gene in die sel
voorkom, kan karsinogenese veroorsaak, die proses waardeur ’n normale sel in ’n kan-
kersel omskep word en gewoonlik in die volgende drie stappe gedoen word: inisiasie,
proliferasie en progressie. Kankerstemselle word gereguleer deur komplekse interaksies
met die komponente van die tumor mikro-omgewing deur netwerke van sitokiene en
groeifaktore. Die tumor mikro-omgewing (TME) bestaan uit verskillende seltipes, in-
sluitende aangebore en aanpasbare immuun selle, en sitokiene wat die aktivering of
inhibisie van die immuun selle en proliferasie van tumorselle reguleer. Om die rol van
sitokiene te verstaan, kan ’n belangrike rol speel in die stryd teen kanker. Verskeie na-
vorsingsprojekte het die dinamika van hierdie sitokiene ge-ondersoek in die konteks
van kanker om die evolusie van kanker te verstaan vir die verbetering van diagnostiese,
prognostiese en terapeutiese strategiee¨. Hierdie studies is egter meestal beperk tot selle
wat kankerselle direk doodmaak, soos natuurlike vernietigers (NV) en sitotoksiese T
iv
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limfosiete (CTLs of CD8 + T) selle, en hulle eksplisiet nie sitokien-gemedieerde aange-
bore aanpassingsimmuniteit in ’n tumor dinamika. Verder het geen van hierdie studies
selektiewe wiskundige modelle gekombineer met molekuleˆre-vlak / seinweganalise, bi-
ologiese prosesse en verrykde wee¨ wat verband hou met kankersiekte, voorspel nie.
In hierdie studie is ’n nuwe nie-lineeˆre wiskundige model wat sitokien-gemedieerde
aangebore aanpassingsimmuniteit integreer ontwikkel om die sitokien-gemedieerde tu-
mor en immuun seldinamika te voorspel. Numeriese analise van die model het voor-
gestel dat ’n gebrek aan TGF-β remmings-effek tot tumorruiming gelei het, maar die
immuunselle het sonder gebind gegroei en die dravermoe¨ oorskry. Daarbenewens het
ons die nodige toestande vir tumor verwydering deur verskillende parameterwaardes
vasgestel. Vir ’n immuun (effektor) sel wat vanuit ’n rustende toestand geaktiveer moet
word, moet sy geen uitdrukking verander wor. Ons gebruik datastelle van The Cancer
Genome Atlas (TCGA) en ’n uitdrukkingsvlakgebaseerde model om gene wat spesifiek
vir kankerpasie¨nte is, te identifiseer wat bydra tot die regulering van sitokiene in die
konteks van die borskanker siekte. Ons het differensieel uitgedrukte gene (DUG) voor-
spel wat verband hou met borskanker siekte deur gebruik te maak van ’n permutasie-
gebaseerde betekenisanalise van mikro-skikking benadering. Deur gebruik te maak van
’n geselekteerde lys van die DUG, het ons belangrike paaie en verrykde biologiese pro-
sesse geassosieer met borskanker bepaal. Sommige van die geÃr´dentifiseerde bedui-
dende biologiese wee¨ en prosesse, sowel as oor-uitgedruk gene, wat waargeneem word
geassosieer met sel differensiasie of seldeling, kan bydra tot die proliferasie van kanker-
selle. Hierdie wee¨ en oor-uitgedruk gene kan verder geassesseer word om na te gaan of
hulle geskik is as teikens vir die borskanker siekte.
Keywords: Tumor selle, immuun selle, sitokiene, differensieel uitgedruk gene.
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Chapter 1
Introduction
Cancer is a leading cause of morbidity and mortality both in the developed and develop-
ing world [1]. Approximately 1.67 million new cases were diagnosed and 0.522 million
cancer-related deaths recorded during the year 2012 compared to 2011 [1, 2]. This makes
cancer research an interesting public health topic and a lot of effort towards research is
being put to understand the mechanisms of cancer evolution and progression. Accord-
ing to the world health organisation (WHO) report, breast cancer is the most (25.2%)
common incident site amongst women, making it the leading cause of death among
women [1]. Figure 1.1 gives a summary of the estimated incidence and mortality rates
of breast cancer in 2012.
The incidence rates in the developed world is greater compared to the developing world
and the mortality rates are comparable as shown in Figure 1.1. The increase in breast
cancer incidence in the developing world can be associated with the consequences of
globalisation, increased urbanization and a transition in behaviour, in terms of adopting
western lifestyles which promotes physical inactivity and bad dietary habits [3, 4]. Ap-
proximately 21% breast cancer deaths are attributed to risk factors, such as alcohol use
(5%), physical inactivity (10%), overweight and obesity (9%) [5]. Although, avoiding
exposure to these behavioural risk factors might reduce breast cancer incidence, it is not
sufficient to fight breast cancer [3–5]. Therefore, healthcare guidelines for early detec-
tion methods, early prognosis and accurate selection of therapy remain the cornerstone
of early cancer detection, control and improved overall survival rate [3, 6]. The relative
survival rate of breast cancer patients depends on factors, such as the number of axillary
lymph node involved, cancer size (diameter), presence of hormone receptors, treatment
strategy, stage of the disease and geographical location of the patient [7]. Despite major
1
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Figure 1.1: Worldwide estimated breast cancer incidence and mortality rate in 2012. The
estimates are age-standardized per 100,000. Adapted from http://globocan.iarc.fr/
.
advances in treatment which usually involve both non-surgical and surgical removal
of the breast (mastectomy) or the tumour and surrounding tissue (lumpectomy), breast
cancer remains a clinical challenge affecting numerous patients both in the developed
and developing world [1, 6].
In the next sections, we discuss about carcinogenesis(evolution of cancer), immune re-
sponse to cancer disease, cytokines promoting carcinogenesis, RNA-Seq expression data
analysis, motivation, objectives and significance of this study.
1.1 Evolution of cancer disease
Cancer is a complex tissue made up of different cell types that actively work together.
In the 19th Century, Rudolf Virchow hypothesized that the origin of cancer was at sites
of chronic inflammation [8]. Tumour micro-environment (TME) contains inflammatory
cells which are a useful component of tumour progression. Occurrence of cancer is often
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triggered by multiple changes in the genetic make up of normal cells, such as deletion,
insertion, substitution, translocation, inversion, or gene amplifications triggered by ei-
ther internal (genetic) or external (exposure to chemical) carcinogens [9, 10].
Early work on cancer growth focussed on investigating how ’normal’ cells mutate into
cancer cells [8, 11–13]. The onset of tumour formation happens in the absence of a vas-
cular network. Tumour cells have the ability to secrete tumour angiogenic factors (TAF)
that stimulate proliferation of endothelial cells to create their own blood vessels (an-
giogenesis) and promote its growth [9, 10, 14]. After developing a vascular network,
tumour cells will have supply to nutrients and oxygen to support its development and
proliferation. TME consist of various cell types such as fibroblasts and epithelial cell
types, innate and adaptive immune cells, mesenchymal cell types and cells that form
blood and lymphatic vasculature [12, 13]. Cancer cells use the following mechanisms to
promote its growth and proliferation as highlighted by Hanahan and Weinberg [9], Bel-
lomo and Preziosi [10]
1. Normal cells in a certain tissue that are programmed to die resist any anti-growth
signals by deactivating p53 signals, turning rogue and growing uncontrollably [9].
2. Tumour cells produce angiogenic factors (TAF) that promote angiogenesis and its
survival [9, 10, 14].
3. Tumour cells decrease immunogenecity by secreting anti-inflammatory cytokines,
loosing major histocompatibility complex (MHC) molecule expressions, and con-
verting anti-tumour immune cell signals to pro-tumour signals [15–18]
4. Tumour cells stimulate immune cells to secrete soluble molecules, such as cy-
tokines, chemokines and other growth signals to promote its development and
progression [9].
5. Tumour cells require higher metabolisms compared to normal cells therefore, they
reprogram pathways regulating cell metabolism to sustain its rapid proliferation [9].
6. Aggressive tumour cells spread to distant sites by evading immune surveillance,
and invading the adjacent local tissues [9].
In summary, cancer cells have acquired the ability to evade immune surveillance [10, 12]
and in the next section, we explore how the immune system responds to cancer disease.
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1.2 The immune response to cancer disease
The immune system has two main branches, the innate and adaptive immunity [12].
Innate immune cells include macrophages, dendritic cells (DCs), natural killer (NK) cells
and adaptive immune cells include B and T cells [12]. B-cells recognize antigens while T
cells recognize MHC molecules and APCs [12, 19]. The innate immunity is the first line
of defence and the adaptive immunity takes time to respond as it adapts to defend the
host’s body against specific antigens[12, 20].
The immune system plays three keys roles in destroying tumours; firstly, it suppresses
viral infections that may cause viral-induced tumours secondly, it eliminates pathogens
quickly or worsens the inflammatory environment not to be conducive for tumour for-
mation and thirdly, it recognizes and eliminates tumour-specific antigens expressed by
tumour cells before they cause harm [21]. The presence of a tumour stimulates an im-
mune response and the fate of the tumour is highly dependent on the response of host’s
immune system, initial number and type of tumour cells, and the surrounding envi-
ronment in the host [20]. The interaction between cells in an immune response are
bi-directional and often controlled by tissues, cytokines, chemokines and other solu-
ble chemical factors [22, 23]. Figure 1.2 illustrates tumour progression in the presence of
an immune response and cytokines.
Macrophages and DCs are the most potent antigen presenting cells (APCs) of the im-
mune system [24]. Immature macrophage monocytes are released from the bone mar-
row into the blood stream, and tissues to undergo maturation into resident macrophages
that have proteins on their surface to recognize and directly bind to the surface of tu-
mour cells [12, 25]. Activated macrophages engulf tumour cells, produce battle cy-
tokines that send danger signals to activate DCs and other immune cells by presenting
an antigen attached to MHC class II molecules on its surface [12]. When such activated
DCs leave the tumour site, they initiate and amplify an immune response [12, 26, 27].
A mature DC (mDC) can express multiple co-stimulatory molecules and cytokines that
are important in priming effector T cell responses, activating resting NK (rNK) cells,
and CD8 T cells [12, 27] as shown in Figure 1.2. The activity of DCs are regulated by
cytokines secreted by macrophages and NK cells [28].
In the presence of tumour antigens, CD8+ T cells differentiate into cytotoxic T lympho-
cytes (CTLs), CD8+ T cells differentiate into type 1 (Th1), type 2 (Th2), type 9 (Th9),
type 17 (Th17), type 22 (Th22), and FoxP3+ cells which have very distinct biological
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Figure 1.2: Activated macrophages engulf tumour cells, secrete cytokines to send signals
to activate dendritic cells and other immune cells. The outcome can favour either a
tumour-promoting response or an anti-tumour immune response. Diagram adapted
from De Visser et al. [13]
roles [29, 30]. The crucial difference between CD4+ T cells and CD8+ T cells is that they
recognize antigens in different pathways. CD8+ T cells recognise endogenous antigens
presented by MHC class I molecules while CD4+ T cells recognise antigens presented by
MHC class II molecules [17, 31]. Cytokines are considered the main determining factor
in the initial differentiation of T cell subsets and they are used to activate an immune
response. In the next section, we look into the role of cytokines in promoting tumour
development.
1.3 Exploring cytokine world during carcinogenesis
Cytokine signals regulate the activation or inhibition of immune cells and prolifera-
tion of tumour cells [10]. Cytokines have three functional classes; pro-inflammatory,
anti-inflammatory, and lymphocytes growth factors or cytokines that can polarize an
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immune response due to the presence of an antigen [32, 33]. Type 1 immune signals in-
cluding type 1 macrophages, CTLs, NK and Th1 cells highly produce pro-inflammatory
cytokines whereas anti-inflammatory cytokines are secreted by tumour cells and type 2
immune signals, such as type 2 macrophages, Th2, and Th17 cells [12, 16, 29, 33]. The
balance of cytokines in a TME is critical for the human body’s internal stability. Under-
standing the role of cytokines during tumour development, proliferation, and progres-
sion is not easy because of its pleiotropic, antagonistic, redundant and multifunctional
nature [19, 32]. For example, IFN-γ and IL-2 stimulate the proliferation and differenti-
ation of effector cells, such as Th1 cells but, at a later stage it can promote apoptosis of
these effector cells [34].
Tumour cells provoke changes in the local cytokine environment to promote its devel-
opment and progression [19]. A majority of solid (aggressive) tumours secrete anti-
inflammatory cytokines to promote apoptosis of effector cells, inhibit proliferation and
activation of immune cells [12, 16, 29, 33, 35]. For example, (i) transforming growth fac-
tor (TGF)-β inhibits the activation and expansion of CTLs and B cells and this reduces
tumour antigen expression [36], (ii) IL-10 inhibits anti-tumour cytotoxic T-cells, antigen
presentation, and MHC class II expression on tumour cells [37], (iii) IL-6 and TGF-β
inhibits IL-2 production, favours angiogenesis, proliferation, and invasion of breast can-
cer [33, 36], (iv) IL-23 reduces tumour-suppressing effects of macrophages and cytotoxic
T lymphocytes [14, 37]. To counter the effect of tumour cells, type 1 immune signals
secrete TNF-α to activate macrophages, NK cells and enhance the cytotoxicity of NK
cells [12], IL-12 and TNF-α to stimulate the differentiation of CD8+ T cells, IL-15 to pro-
mote NK cell differentiation in vivo, and IL-1 and IL-18 to increase the potential effect
of IL-12 receptor on NK cells [18, 38]. The review in Dranoff [19] provides an extensive
overview of cytokines during the development of cancer.
Cytokines have been approved as diagnostic, prognostic and therapeutic agents in var-
ious diseases [32]. An example is IL-2 which is the only pro-inflammatory cytokine that
has been approved for cancer treatment. On the downside, its effects are harsh and not
easily tolerated by most patients and it has a low efficacy in treating melanoma and re-
nal cell carcinoma [32]. Cytokine activate immune cells and for an immune cell to be
activated from a resting state, its gene expression must be altered [12]. In the next sec-
tion, we provide an overview of RNA-Seq experiments and analysis of gene expression
data.
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1.4 Overview of RNA-Seq gene expression data analysis
The evolution of a cell is regulated by the genes contained in its nucleus [10]. According
to UniProt Knowledgebase database (http://www.uniprot.org), the human genome
contains 20,230 manually reviewed protein-coded genes. A correct gene expression
is essential for normal cellular function, gene alteration can lead to over-expression or
under-expression of corresponding gene, suppression of proteins and translation of new
protein-causing disease. When the right combination of genes are mutated then one may
develop cancer disease.
Due to advancements in technology, the next generation sequencing (NGS) application
to transcriptomics (RNA-Seq) is increasingly being used to simultaneously monitor the
behaviour patterns of thousands of nucleic acid sequences or proteins [39]. The sequenc-
ing framework of RNA-Seq enables investigation of all RNAs in a sample, characteriz-
ing their sequences and quantifying their abundances (count) at the same time [40].
Statistical approaches have been proposed by many studies to analyse RNA-Seq gene
expression data in pursuit of finding differentially expressed genes (DEGs), that can be
used to explain phenotypic differences between groups(conditions), cell types and tis-
sue samples [41].
Statistical methods have been proposed to predict bio-marker genes that are expressed
differently between samples or conditions. A gene is said to be differentially expressed
if there is a difference in RNA-Seq per cell produced under different conditions. The
goal of gene expression analysis is to identify biological pathways and processes asso-
ciated with a selected gene set. Gene-set based methods are preferred to single-gene
based methods when investigating the phenotypic differences at pathway and func-
tional level [42]. Genes have multiple annotations in various databases, implying that
a gene may have multiple notations, this often leads to gene annotation ambiguity. Re-
sources, such as Gene Ontology (GO) [43], Gene Ontology Annotations (GOA) [44] or
Kyoto Encyclopedia of genes and genomes (KEGG) [45], provide information about bio-
logical processes, functions and pathways of DEGs. Understanding biological processes
and pathways of DEGs associated with breast cancer might lead to a more targeted and
optimal approach to breast cancer treatment [2].
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1.5 Motivation
The immune system represents a complex interacting network with most of the inter-
actions between innate and adaptive immunity relying on the presentation of antigens,
cytokines and chemokines [12, 23]. Cytokines have been used in medicine, as diagnos-
tic, prognostic and therapeutic agents in various diseases [32]. However, cytokines have
multifunctional characteristics, for example TGF-β promotes healthy (tumour-free) cell
growth and function, but also enhances tumour growth and metastasis by inhibiting
immune response [36]. Thus, understanding the role of cytokines in tumour-immune
cell dynamics can be crucial in the fight against cancer. To our best knowledge, we
did not find (i) a model that implicitly investigates cytokine-mediated innate-adaptive
immunity in the presence of a tumour and (ii) research studies that combine cellular-
level mathematical models with molecular-level analysis to predict DEGs that regulate
cytokine production.
1.6 Objectives and significance of this study
In this study, we will
1. Predict known cytokines that play a crucial role in the activation or inhibition of
an immune response and development of tumour.
2. Develop and analyse a mathematical model to investigate the role of cytokines in
tumour-immune cell dynamics.
3. Establish conditions necessary for tumour clearance.
4. Predict DEGs that can be used for breast cancer bio-marker discovery and regula-
tion of cytokine production.
5. Determine enriched pathways and biological processes associated with breast can-
cer.
Cancer cells are highly heterogeneous, they have different genetic make-up and have
developed resistance to drugs during and after treatment. The aim of this study is to
provide insights into cytokine-mediated tumour-immune cell dynamics and DEGs, en-
riched pathways, and biological processes across breast cancer samples that promote
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carcinogenesis. These results can be useful for cancer drug discovery and will contribute
to the current progress in cancer treatments, such as chemotherapy and immunotherapy.
1.7 Outline
The thesis is structured as follows
1. Chapter 1 is this introduction that briefly reviewed cancer evolution, immune cell
response, cytokines during carcinogenesis, gene expression data set analysis, and
gave the motivation and objectives of this study.
2. Chapter 2 gives a brief review of the mathematical models that have been pro-
posed to explore tumour-immune cell dynamics with and without cytokine-mediated
effects.
3. Chapter 3 provides a review of a new cellular-level mathematical model proposed
in this study. The model is used to predict cytokine-mediated tumour-immune
cell dynamics. In this Chapter, we investigate steady states, and their stability and
numerical simulations of the model.
4. Chapter 4 analyses gene expression data set for breast cancer patients and healthy
(tumour-free samples) to predict DEGs that are either over-expressed or under-
expressed across the two samples. Here, we use the DEGs to predict enriched
pathways and biological processes associated with breast cancer disease.
5. Chapter 5 discusses the findings of this study and future directions.
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Literature Review
2.1 Brief review of the biological background
The main function of the immune system is to monitor tissue homoeostasis, to protect
against invading or infectious pathogens and to eliminate damaged cells [12]. Over the
past decade, studies have indicated that the immune system can recognize and partially
suppress nascent and immunogenic tumours. The promptitude of an immune response
is a consequence of the availability of innate immune cells that express their responding
receptors before exposure to the stimulants [12].
Innate immune cells are a population of lymphocytes that are always present and con-
trol cancer cells. Human NK cells are made up of approximately 10% of the peripheral
blood lymphocytes, these cells are phenotypically characterised by the presence of CD56
and absence of CD3 [46]. NK cells can be activated due to low levels of MHC I, over ex-
pression of CD27, gp96 or NKG2D ligands [28] or up regulating ligands for stimulatory
and co-stimulatory molecules expressed on NK cells, such as NKG2D, CD244, CD28 and
CD137 [18]. An infiltration of NK cells in a TME has been linked to favourable progno-
sis in cancer patients [47]. Because cancers often express stress-related genes MICA and
MICB, which function as ligands for NKG2D receptors expressed by NK cells, and cyto-
toxic lymphocytes [19]. The maturity and apoptosis of DCs is dependent on the NK cell
activating receptor NKp30 although, this process can be counter-regulated by killer-cell
immunoglobulin-like (KIR) and NKG2A inhibitory receptors [28, 48]. NK are known to
be the main supply of IFN-γ at the early stage of tumour growth. Production of IFN-γ
secreted during NK cell-mediated tumour rejection is critical for priming of Th1 cells,
activation or induction of MHC I molecules in DCs and tumour cells, and proliferation
10
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of CTLs particularly when tumours express CD70 or CD80 and CD8649 [28]. A mature
DC (mDC) can express multiple co-stimulatory molecules, growth factors and cytokines
that are important in priming of effector T cell response, activating of resting NK (rNK)
cells, enhancing the cytotoxicity of NK cells, promoting the survival of NK cells and
CD8+ T cells and that affect endothelial, epithelial and mesenchymal cells in the local
TME [12, 18, 27, 38].
The adaptive immune cells are the mediators of immunity [12]. An adult human being
has about 300 billion of T-cells [12]. During the early stage of tumour growth, CD4+ T
cells secrete cytokines, such as IFN-γ to help expand and promote adequate function-
ing of CD8+ T cells [17, 30]. However, CD8+ T cells lack the ability to orchestrate a
broad anti-tumour response which some of the CD4+ T cells subsets in Figure 2.1 have.
Sometimes CD8+ T cells fail to function properly in the absence of CD4+ T cells [17]
because tumour cells have the ability to frequently change by processing and secreting
endogenous antigens or immune-suppressive soluble factors, activating co-stimulatory
molecules or losing of key molecules required for antigen recognition and presenta-
tion [31].
At a later tumour stage naive CD4+ T cells can become polarized into various subsets
that are directly involved in mediating in vivo tumour regression or evasion [17, 29].
There exists many subsets of T cells but Th1, Th2 and Th17 cells are commonly studied
as they have an immune response towards/during an invasion. The first subsets to be
identified were Th1 and Th2 cells [49]. A new CD4+ T cell subset, Th17 was identified
in 2015, it plays a central role in inflammation and auto-immune diseases but it is also
known to support tumour growth [30]. The presence of Th2 and Treg promote tumour
growth by suppressing the commitment of both the CD4+ and CD8+ T cells. Th1 results
in the regression of tumour and supports the differentiation of CD8+ T cells whereas
Th2 suppresses it. Studies indicate an increase in tumour incidence with inflammation
and several cytokines such as TNF-α, TGF-β, IL-6 and IL-23 have been linked to tumour
promoting inflammation and Th17 lineage [14]. T cell subsets are regulated by differ-
ent signal transducer and activator of transcription (STAT) and transcription factor [27].
Figure 2.1 illustrates the activation and differentiation of these T cell subsets.
CD4+ T cells secrete cytokines like IL-2 when induced by APCs to stimulate and pro-
mote the proliferation and differentiation of T cells [36]. Using Figure 2.1, at the tran-
scriptional level, Th1 development is induced by pathogens that stimulate production
of IFN-γ and IL-2 through signals from STAT4, STAT1 which then activates T-box tran-
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Figure 2.1: T cells are activated and can different into various subsets due to the presence
of tumour cells, transcription factors and cytokines.
scription factor T-bet/Tbx21 [30, 50]. Th2 is produced when IL-4 stimulates the expres-
sion of GATA3 transcription factor through signals from STAT6 and Th17 require STA3
and the retinoic-acid-related orphan receptor (RORγt) for its commitment and differ-
entiation [30, 50]. CD4+ T helper cells can be differentiated into Treg that are defined
by expression of forkhead box P3 (FoxP3) and they play an anti-inflammatory role [50].
Treg and Th17 have shown to be dependent on TGF-β for their differentiation [51]. The
addition of IL-6 or IL-21 to TGF-β results in the differentiation of Th17 [52].
Although, it is still unclear whether both IL-6 and TGF-β influence the commitment and
development of Th17 cell lineage. For instance, experiments on mice and even Mangan
et al. [51] demonstrated that TGF-β is required for the differentiation of Th17 commit-
ment independently of IL-23 but Wilson et al. [53] demonstrated that TGF-β and IL-6 do
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not play any key role in the commitment and differentiation of Th17 T cells and demon-
strated that IL-23 and IL-1β are responsible for the commitment of Th17 T cells in vitro.
Wilson et al. [53] further observed that presence of IL-6 and TGF-β even blocked IL-23
induced development of Th17 in humans. Although, similar results were observed in
the inhibiting effect of IL-4 and IL-12 on the IL-23 Th17 development in humans and
mice. Contrarily to observations made in mice experiment, Wilson et al. [53] showed
that TGF-β may actually inhibit the differentiation of Th17.
Majority of solid cancer cells do not have MHC class II molecules on their surface,
but tumour cells up regulate MHC class II molecules upon exposure to IFN-γ pro-
duced by CD4+ T in the presence of interleukin (IL)-12 produced by mature DCs and
macrophages [35, 54]. MHC expression on tumour cells increases their immunogenecity
and cell-surface NK receptors recognizes MHC I molecule signal which activates NK
cell functions to selectively lyse tumour or infected pre-cancerous cells [18].
Tumour-immune cell interactions can be complex and mathematical models are devel-
oped to (i) understand the dynamics of tumour cells and the components of its local
TME, (ii) uncover basic mechanisms of these dynamics and (iii) identify new hypothe-
ses or ideas that can be tested experimentally both in vivo and in vitro without incurring
a lot of cost [55]. In the next section, we briefly discuss mathematical models that have
been developed to explore tumour-immune cell dynamics.
2.2 Brief review of tumour-immune mathematical models
Tumour-immune models have been around for almost 3 decades [55]. Significant efforts
have been made towards understanding cancer evolution using mathematical models.
These models can be categorised as (i) molecular-level models developed to understand
signalling pathway involved in the activation of an immune response, (ii) cellular-level
models developed to understand the role of innate and adaptive cells, and (iii) tissue-
scale models developed to understand the distribution of immune cells inside solid tu-
mours [55]. We refer the reader to Eftimie et al. [55] for an extensive review describing
these categories of mathematical models.
Much of the original work on investing tumour-immune cell dynamics using mathemat-
ical models was done by Kuznetsov et al. [56] and colleagues. Over the past 20 years,
intensive research has focused on the interactions between tumour cells and immune
effector cells, such as (i) innate immune cells [56], (ii) adaptive immune cells [56], (iii)
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combination of innate and adaptive immune cells [57–59] (iv) cytokines and the adap-
tive immune cells [34, 36, 60, 61]. Reviews in Eftimie et al. [62], Adam and Bellomo [63]
provide a comprehensive summary of mathematical models proposed to investigate and
understand tumour-immune dynamics.
Cytokines play a crucial role in activating an immune response, priming of T helper
cells, and promoting tumour development. Tumour-immune models have been pro-
posed to investigate cytokines implicitly [57], as state variables [36, 60, 61], or as quasi-
steady states because cytokines evolve (are produced and decay) at a much faster time
scale than the immune cells [34]. The first model to explore the role of cytokines, specifi-
cally IL-2 was proposed by Kirschner and Panetta [61], who developed a three-equation
model referred to as Kirschner-Panetta (KP) system as shown in Equation 2.2.1
dE
dt
= cT − µ2E + p1EILg1 + IL + s1, (2.2.1a)
dT
dt
= r2(1− bT)− aETg2 + T , (2.2.1b)
dIL
dt
=
p2ET
g2 + T
− µ3 IL + s2, (2.2.1c)
with initial conditions, E(0) = E0, T(0) = T0, IL(0) = IL0 , and where E is the acti-
vated immune effector cells that destroy tumour cells T, stimulated by IL-2 IL. The first
Equation 2.2.1a represents the rate of change of immune (effector) cells population. Ef-
fector cells are recruited at a rate c by the antigenicity of tumour cells and s1 by external
sources (treatment effect). The proliferation of effector cells is simulated at a rate p1 by
IL-2. The saturated effects of an immune response g1 is modelled as the third term using
Michaelis-Menten form. Effector cells have a natural death rate µ2. The second Equa-
tion 2.2.1b represents the rate of change of tumour cell population. Tumour cells have an
intrinsic growth rate r2 and a carrying capacity b. The strength of the immune response
a is dependent on the saturation effect of tumour cells g2. The third Equation 2.2.1c
represents the concentration level of IL-2. IL-2 is recruited at a rate p2 by its interaction
with tumour cells with a half saturation constant g2 and by external supply source s2
(treatment term). IL-2 degrades at a rate µ3.
The study in Kirschner and Panetta [61] identified that high amounts of IL-2 together
with immunotherapy can lead to tumour clearance, but at the expense of uncontrolled
immune over-stimulation, a condition where the immune system grows without bound [61].
The study in Arciero et al. [36] included one more equation for TGF-β to the Kirschner-
Panetta (KP) system in Equation 2.2.1. The study in Arciero et al. [36] found that aggres-
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sive tumours secreted TGF-β which inhibited IL-2 production, reduced antigen expres-
sion, activation of immune effector cells and tumour detection by effector cells. These
mechanisms promoted tumour development and progression. Arciero et al. [36] in-
cluded a fifth equation for small interfering RNA (siRNA) therapy to the KP system
of equation. This therapy inhibited the production of TGF-β by blocking TGF-β syn-
thesis. Unfortunately, the therapy did not yield a persistent tumour dormancy, but it
offered mechanisms to counter the effects of TGF-β such as IL-2 inhibition, tumour es-
cape and growth [36]. Aggressive tumours were more destructive compared to their
passive counterparts that were not secreting TGF-β [36].
In the next Chapter, we propose and analyse a new ten-equation non-spatial mathe-
matical model. The model builds on the structure of models proposed by Yates et al.
[34], Kuznetsov et al. [56], Eftimie and Hamam [57] and it adds tumour-promoting effect
of a third subset of T helper cells known as Th17 cells, and tumour-suppressing effect of
NK cells together with the role cytokines play in activating an immune response.
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Modelling cytokine-mediated
tumour-immune cell dynamics
3.1 Introduction
Mathematical models can be used to improve our understanding of dynamics that un-
derlie an immune response. The idea here, is to introduce anti-inflammatory cytokines
(IL-6, IL-10, IL-23, and TGF-β) and pro-inflammatory cytokines (IL-12, IFN-γ, TNF-α) as
quasi-steady states, model there influence in activating innate (type 1 and 2 macrophages,
NK cells) and adaptive immune cells (CTLs, Th0, Th1, Th2, Th17 cells). In the next sec-
tions, we develop a new mathematical model, analyse the model and draw conclusions
from the analysis. Due to lack of spatial data from literature and clinical experiments,
the model developed will not capture spatial dynamics.
3.2 Mathematical model description
Figure 3.1 represents a schematic diagram describing cytokine-mediated tumour-immune
cell dynamics considered in this study.
Cancer "danger signals" and antigens activate the innate and adaptive immunity me-
diated by cytokines as shown in Figure 3.1. Resting macrophages are activated by the
presence of tumour antigens and they can differentiate into two subsets type 1 (M1) and
type 2 (M2) macrophages [12]. According to Figure 3.1, the activated M1 macrophages
can activate naive CD4+ and CD8+ T cells stimulated by cytokines, such as IL-12 and tu-
mour necrosis factor (TNF)-α [12, 64]. In the presence of tumour antigens, CD8+ T cells
16
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Figure 3.1: Schematic diagram to represent cytokine-mediated innate-adaptive immu-
nity in the presence of tumour cells. Resting macrophages recognize tumour antigens.
Activated macrophages have the ability to engulf tumour cells, secrete cytokines to send
signals to activate CTLs, naive T helper (Th0) cells and resting NK (rNK) cells. The out-
come of tumour-immune cell dynamics can favour a type 2 immune response at the
expense of type 1 immune response or vice versa.
differentiate into CTLs and T helper cells can differentiate into various subsets includ-
ing type 1 (Th1), type 2 (Th2), type 17 (Th17) cells which have very distinct biological
roles [29, 30]. Th1 cells can activate M1 macrophages, CTLs and B cells [12]. Type 2
immune signals (M2 macrophages, Th2 and Th17 cells) promote tumour development
by producing tumour-promoting cytokines, such as IL-6, IL-10, IL-23 and TGF-β that in-
hibit the activation of type 1 immune signals (M1 macrophages, CTLs, NK and Th1 cells)
and proliferation of tumour-suppressing cytokines, such as IL-12, interferon (IFN)-γ, IL-
2, TNF-α. NK cells can kill/destroy without being activated but, they require TNF-α and
IFN-γ to increase there cytotoxicity and cell population [12].
The ODE model developed for this study describes dynamics of the following variables
as they vary through time t
1. Cytokine; tumour-promoting cytokines including IL-6, IL-10, IL-23, TGF-β and
tumour-suppressing cytokines including IL-12, TNF-α and IFN-γ secreted by im-
mune and tumour cells.
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2. Innate cell; activated type 1 macrophages (M1) M1(t), type 2 macrophages (M2)
M2(t) and natural killer (NK) cells Nk(t).
3. Adaptive cell; cytotoxic T lymphocytes (CTLs) cells Tc(t), activated naive T helper
(Th0) cells T0(t), type 1 T helper (Th1) cells T1(t), type 2 T helper (Th2) cells T2(t)
and type 17 T helper (Th17) cells T17(t).
4. Infective or infected cell; cancer C(t) and infected pre-cancerous cells Pc(t).
To simplify the model, we made the following assumptions
3.2.1 Model assumptions
1. Tumour cells and immune cells grow logistically up to a carrying capacity βi in
the absence of an immune response or tumour cells, respectively [56, 65, 66]. This
concept was first explained by Gompertz [66], the study observed a sigmoidal
population growth curve when modelling cell replication and death.
2. The adaptive immunity is dependent on signals from the innate immunity [12].
Innate immune cells (NK cells, M1 and M2 macrophages ) are always present and
can kill tumour cells but, adaptive immune (CTLs, Th0, Th1, Th2, Th17) cells have
to be activated to kill.
3. Cytokines can be produced by innate immune cells, T cells and other cells within
the TME, such as neutrophils, eosinophils, and basophils [57]. We made an as-
sumption that these other cells within the TME have a negligible influence to the
production of cytokines.
4. Tumour cells, Tregs, M2 macrophages, Th17 cells produce large amounts of TGF-β,
IL-6, IL-10 and IL-23 to inhibit any type 1 immune signals [37]. Suppressive effects
of Tregs and Th17 are modelled implicitly [37]. We assumed that Tregs increase the
population of IL-10 and TGF-β by a factor S2 whereas Th17 increase the population
of IL-6, IL-10 and TGF-β by a factor S1 [14, 29, 67].
5. Cytokines act as growth factors to stimulate proliferation and activation of im-
mune cells [12]. We considered the stimulating effects of cytokines in recruit-
ing/activating immune cells but, ignored/implicitly modelled its effect in pro-
moting the proliferation of immune cells.
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6. IFN-γ inhibits the proliferation of Th17 cells but, not Th2 cells [51]. IL-4, IL-23 and
TGF-β can inhibit the proliferation of type 1 immune signals [27, 34, 37, 57].
3.2.2 Description of model equations
Parameters are used to describe the rate of change of cell population. Table 3.1 summa-
rizes the notations used in describing the model.
Table 3.1: Convention used in naming the parameters in the model
Parameter Description of terms
ξi Production rate of type i signalling molecule (cytokine)
ρi Activation rate of effector cell i by the presence of tumour cells which is
determined by cytokine signals
αi Intrinsic growth rate of cell i
βi Carrying capacity of cell i
δi Inactivation rate of effector cell i due to its interactions with tumour cells
Λc Inactivation rate of tumour cells due to its interaction with effector cells
ηi Inhibition rate of cell i by cytokine i
µi Natural death/degradation rate of cell i
θi Rate of producing new tumour cells by cell i
Si Production rate of cytokines by Th17 cells S1 and Tregs S1
The rate of change of immune and tumour cell population can be described as
Type 1 immune signal = activation + proli f eration− necrosis(inactivation)− apoptosis
Type 2 immune signal = activation + proli f eration− apoptosis(natural death)
Cancer cell = proli f eration + recruitment− necrosis− apoptosis
In f ected(pre− cancerous) cell = production− apoptosis
The equations of the model follow the above description and can be described as shown
below
• Equation for cytokines: Cytokines evolve at a much faster time scale than the im-
mune cells thus, we made an assumption that cytokine dynamics can be described
by a quasi-steady state [34]. Pro-inflammatory (tumour-suppressing) cytokines
are produced at a rate ξ1 by type 1 immune signals. Anti-inflammatory (tumour-
promoting) cytokines are produced at a rate ξ2 by type 2 immune signals and
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tumour cells. We made an assumption that, Th17 cells boost the production of IL-
6, IL-10 and TGF-β by a factor S1 whereas T regulatory cells boost the production
of IL-10 and TGF-β by a factor S2. Table 3.2 lists quasi-steady states of these cy-
tokines, where superscript i, a and c denote cytokines secreted by the innate, adap-
Table 3.2: Key cytokines involved in tumour-immune interactions.
Tumour-promoting cytokines Tumour-suppressing cytokines
Ii4 = ξ2M2 I
i
γ = ξ1Nk
Icβ = ξ2S1S2C I
i
12 = ξ1M1
Ic23 = ξ2C I
i
α = ξ1M1
Ii6 = ξ2S2M2 I
a
γ = ξ1(T1 + Tc)
Ic10 = ξ2S1S2C I
a
α = ξ1T1
tive and tumour cells, respectively. For simplicity, we considered all cytokines at
a population-level, and made an assumption that cells, such as neutrophils and
eosinophils have negligible effect to the concentration of cytokines.
• Equation for Type 1 macrophages:
The first term of the equation describes the recruitment rate. Type 1 macrophages
are activated at a rate ρm due to the presence of cancer cells stimulated by TNF-
α [12, 64]. Where Ci = C/(κ + C) represents the saturation effect of cancer cells
and κ is the half saturation level of cancer cells that stimulates an immune re-
sponse [60]. The second term describes the proliferation rate. M1 and M2 grow
logistically at a rate αm up to a carrying capacity βm. The proliferation of effec-
tor cells, such as M1 macrophages is inhibited at a rate η3 by IL-23 and TGF-
β [27, 34, 37, 57]. The interaction between tumour cells and M1 macrophages might
lead to its deactivation at a rate δm. Macrophages (M1 and M2) have a half-life of
1/µm. The dynamics of M1 macrophages can be represented by the following
equation
dM1
dt
= ρm IαCi +
αm M1
(
1− M1βm
)
1+ η3(Iβ + I23)
− δm M1C− µm M1.
• Equation for Type 2 macrophages:
Type 2 macrophages proliferate at a rate ρm in the presence of cancer cells stimu-
lated by IL-4 and IL-10 which can be secreted by Th2 cells [57, 58]. IFN-γ antag-
onizes the secretion of TGF-β, IL-6, and IL-10 [27]. Therefore, the proliferation of
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M2 macrophages is inhibited by IFN-γ at a rate η1 [57]. The following equation
describes the rate of change of the population of M2 macrophages
dM2
dt
= ρm I10Ci +
αm M2
(
1− M2βm
)
1+ η1 Iγ
− µm M2.
• Equation for Natural Killers:
NK cells’ killing ability is stimulated by IL-2 and IFN-γ secreted by Th1 and it-
self [12]. Natural killer cells are activated at a rate ρK due to the presence of cancer
cells and TNF-α produced by Th1 cells and macrophages [12, 37]. NK cells grow
at a rate αk up to a carrying capacity βk stimulated by IL-2 and IFN-γ secreted by
Th1 and NK cells [12]. TGF-β and IL-23 inhibit the proliferation of NK cells at a
rate η3 [27, 37]. NK cells’ interaction with cancer cells results in its inactivation at
a rate δk and they have a half-life of 1/µk. The following equation describes the
rate of change of the population of NK cells
dNK
dt
= ρk IαCi +
αkNk
(
1− Nkβk
)
1+ η3(Iβ + I23)
− δkNkC− µkNk.
• Equation for cytotoxic T cells (CTLs):
IL-12 plays a major role in the activation and differentiation of T cells [68]. CD8+
are activated at a rate ρ8 due to the presence of tumour cells stimulated by IL-
12 which can be secreted by M1 macrophages [12, 68]. CTLs proliferate at a rate
αt up to a carrying capacity βt promoted by IL-2 and IFN-γ secreted by NK and
Th1 cells [17, 69]. TGF-β inhibits the proliferation of CTLs at a rate η3 [14, 34, 53].
Tumour cells kill CTLs at a rate δt and they have a half-life of 1/µ8. The following
equation describes the rate of change of the population of CTLs
dTc
dt
= ρ8 I12Ci +
αtTc
(
1− Tcβt
)
(1+ η3 Iβ)
− δtTcC− µ8Tc.
• Equation for activated helper T (Th0) cells:
Naive CD4+ T cells are activated at a rate ρt in the presence of tumour cells stim-
ulated by IL-12 [35, 68]. Th0 cells proliferate at a rate αt up to a carrying capacity
βt in the presence of IFN-γ produced by NK cells [30, 67]. The proliferation of Th0
cells is inhibited at a rate η3 by TGF-β [14, 34, 53]. Helper T cells can differenti-
ate into three major subsets including Th1, Th2 and Th17 cells [28, 30] depending
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on the cytokines in their environment. We implicitly modelled the differentiation
of T cell subtypes. Tumour cells destroy/kill helper T cells at a rate δt and they
decay at a rate µt. Activated Th0 cells differentiate into various subsets including
Th1, Th2 and Th17 cells [28, 30] that is highly dependent on cytokines in the local
environment. The differentiation of T cell subtypes was modelled implicitly. The
following equation describes the rate of change of the population of Th0 cells
dT0
dt
= ρt I12Ci +
αtT0
(
1− T0βt
)
(1+ η3 Iβ)
− δtT0C− µtT0.
• Equation for type 1 T helper (Th1) cells:
Helper T cells differentiate into Th1 cells at a rate ρt if the tumour site is rich in
IL-12 [58, 60, 67]. IL-2 stimulates the proliferation of Th1 effector cells [12]. TGFβ
inhibits the proliferation of Th1 cells at a rate η3 and by IL-4 at a rate η2 [14, 16, 37,
53]. The following equation describes the rate of change of the population of Th1
cells
dT1
dt
= ρt I12T0 +
αtT1
(
1− T1βt
)
1+ η3 Iβ + η2 I4
− δtT1C− µtT1.
• Equation for type 2 T helper (Th2) cells:
Th0 effector cells commit to Th2 cells at a rate ρt if the tumour site is rich in IL-
4 [60, 67]. Proliferation of Th2 effector cells is inhibited at a rate η3 by TGF-β [14,
16].The following equation describes the rate of change of the population of Th2
cells
dT2
dt
= ρt I4T0 +
αtT2
(
1− T2βt
)
1+ η3 Iβ
− µtT2.
• Equation for type 17 T helper (Th17) cells:
IL-6 is necessary for the commitment of Th17 cell lineage in breast cancer tissue in
humans [29]. The proliferation of Th17 cells is inhibited at a rate η1 by IFN-γ cy-
tokine [51]. The following equation describes the rate of change of the population
of Th17 cells
dT17
dt
= ρt I6T0 +
αtT17
(
1− T17βt
)
1+ η1 Iγ
− µtT17.
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• Equation for infected pre-cancerous cells:
The first term in the equation describes the rate of appearance of new infections
in the system due to the interaction of cancer cells with type 1 immune signals
like M1 macrophages, CTLs, NK and Th1 cells. Infected pre-cancerous cells can
become cancerous at a rate θI . This compartment is not usually monitored because
of the huge costs involved in measuring the infected cells. Activated CTLs and NK
cells can recognize and kill infected cells at a rateΛc [34]. Infected cells have a half-
life of 1/µI . The following equation describes the rate of change of the population
of infected pre-cancerous cells
dPc
dt
= (δm M1 + δkNk + δt(T0 + Tc + T1))C− (Λc (Tc + Nk))Pc − (θI + µI)Pc.
• Equation for cancer cells:
Cancer cells grow at a rate αc up to a carrying capacity βc [56, 65, 70]. The presence
of M2 macrophage boosts the population of cancer cells at a rate θc [58]. Cancer
cells can be engulfed by M1 macrophages and destroyed by effector cells like CTLs,
Th1, and NK cells at a rate Λc [15, 34, 58]. Cancer cells can inhibit its inactivation
at a rate η3 by producing IL-10 and TGF-β [37]. Apoptosis of cancer cells occur at
a rate µc. The following equation describes the rate of change of the population of
cancer cells
dC
dt
= αcC
(
1− C
βc
)
+ θc M2C + θI Pc −
(
Λc (M1 + Nk + Tc + T1)
1+ η3 Iβ
+ µc
)
C.
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Putting all these equations together, the initial value problem is defined as
dM1
dt
= ρm IαCi +
αm M1
(
1− M1βm
)
1+ η3(Iβ + I23)
− δm M1C− µm M1,
dM2
dt
= ρm I10Ci +
αm M2
(
1− M2βm
)
1+ η1 Iγ
− µm M2,
dNK
dt
= ρk IαCi +
αkNk
(
1− Nkβk
)
1+ η3(Iβ + I23)
− δkNkC− µkNk,
dTc
dt
= ρ8 I12Ci +
αtTc
(
1− Tcβt
)
(1+ η3 Iβ)
− δtTcC− µ8Tc,
dT0
dt
= ρt I12Ci +
αtT0
(
1− T0βt
)
(1+ η3 Iβ)
− δtT0C− µtT0,
dT1
dt
= ρt I12T0 +
αtT1
(
1− T1βt
)
1+ η3 Iβ + η2 I4
− δtT1C− µtT1,
dT2
dt
= ρt I4T0 +
αtT2
(
1− T2βt
)
1+ η3 Iβ
− µtT2,
dT17
dt
= ρt I6T0 +
αtT17
(
1− T17βt
)
1+ η1 Iγ
− µtT17,
dPc
dt
= (δm M1 + δkNk + δt(T0 + Tc + T1))C−Λc (Tc + Nk) Pc − (θI + µI)Pc,
dC
dt
= αcC
(
1− C
βc
)
−
(
Λc (M1 + Nk + Tc + T1)
1+ η3 Iβ
+ µc
)
C + θc M2C + θI Pc,

(3.2.1)
with initial conditions
M1(0) = M10, M2(0) = M20, Nk(0) = Nk0, C(0) = C0 > 0 and
Tc(0) = Tc0, T0(0) = T00, T1(0) = T10, T2(0) = T20, T17(0) = T170, Pc(0) = Pc0 = 0.
The initial population of the innate and cancer cells is not zero and its zero for the adap-
tive immune cells. On substitution of the quasi-steady state cytokines in Table 3.2 into
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model (3.2.1) we have
dM1
dt
= ϕ1T1Ci +
αm M1
(
1− M1βm
)
1+ (pi1 + pi2)C
− δm M1C− µm M1,
dM2
dt
= ϕ1T2Ci +
αm M2
(
1− M2βm
)
1+ pi0T1 + pi1C
− µm M2,
dNK
dt
= ϕ1(T1 + M1)Ci +
αkNk
(
1− Nkβk
)
1+ (pi1 + pi2)C
− δkNkC− µkNk,
dTc
dt
= ϕ2M1Ci +
αtTc
(
1− Tcβt
)
1+ pi2C
− δtTcC− µ8Tc,
dT0
dt
= ϕ3M1Ci +
αtT0
(
1− T0βt
)
1+ pi2C
− δtT0C− µtT0,
dT1
dt
= ϕ3M1T0 +
αtT1
(
1− T1βt
)
1+ pi1T2 + pi2C
− δtT1C− µtT1,
dT2
dt
= ϕ3M2T0 +
αtT2
(
1− T2βt
)
1+ pi2C
− µtT2,
dT17
dt
= ϕ3M2T0 +
αtT17
(
1− T17βt
)
1+ pi0T1
− µtT17,
dPc
dt
= (δm M1 + δkNk + δt(T0 + Tc + T1))C−Λc (Tc + Nk) Pc − (θI + µI)Pc,
dC
dt
= αcC
(
1− C
βc
)
−
(
Λc (M1 + Nk + Tc + T1)
1+ pi2C
+ µc
)
C + θc M2C + θI Pc,

(3.2.2)
with initial conditions
M10, M20, Nk0, C0 > 0 and Tc0, T00, T10, T20, T170, Pc0 = 0,
where ϕ1 = ρmξ1 = ρmξ2S1S2 = ρkξ1, ϕ2 = ρ8ξ1, ϕ3 = ρtξ1 = ρtξ2, pi0 = η1ξ1,
pi1 = η2ξ2 = η3ξ2 and pi2 = η3ξ2S1S2.
We prefer to work with the non-dimensionalized form of the model for all the analyses
done on Equation (3.2.2). The model will make sense biologically if parameter values
and solutions are non-negative and unique.
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3.3 Model analysis
For model(3.2.2) to be biologically meaningful, we require the that solutions of the
model exist, and are unique and non-negative.
3.3.0.1 Existence of Unique, Positive Solutions
The non-linear IVP in Equation (3.2.2) can be represented in vector form as
dX
dt
= F(t, X)
= ( f1(t, X), f2(t, X), f3(t, X), f4(t, X), f5(t, X), f6(t, X) f7(t, X), f8(t, X), f9(t, X), f10(t, X))T
with initial conditions
M1(0), M2(0), Nk(0), C(0) > 0 and Tc(0), T0(0), T1(0), T2(0), T17(0), Pc(0) = 0,
and where
f1(t, X) = dM1/dt, f2(t, X) = dM2/dt, f3(t, X) = dNk/dt, f4(t, X) = dT0/dt,
f5(t, X) = dTc/dt, f6(t, X) = dT1/dt, f7(t, X) = dT2/dt, f8(t, X) = dT17/dt,
f9(t, X) = dPc/dt, f10(t, X) = dC/dt.
Theorem 3.3.1 (Existence and uniqueness). Unique solutions exist for model (3.2.2) for all
t ∈ R+ with initial conditions X(0).
Proof. Consider an initial value problem (IVP)
dX
dt
= F(t, X), with initial conditions X(0), (3.3.1)
Equation (3.2.2) can be re-written as F : R+ ×R10+ 7→ R10+ .
The Picard Lindelof theorem discussed by Teschl [64] was used to show existence of
unique solutions. Suppose F ∈ C(U,Rn) where U is an open subset of Rn+1 and initial
conditions (t0, X0) ∈ U. Since the IVP in Equation (3.2.2) and (3.3.1) is differentiable,
this means that F is Lipschitz continuous in X and uniformly continuous with respect
to t. Hence there exists a unique local solution X(t) ∈ C1(t0 − e, t0 + e) to the IVP in
Equation (3.2.2) where e > 0.
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The solutions for model Equation (3.2.2) are unique. Since we are working with cells,
the unique solutions are expected to be non-negative.
Lemma 3.3.2 (Positivity of solutions). If the initial tumour and immune cell densities at time
t = 0 are non-negative M1(0), M2(0), Nk(0), Tc(0), T1(0), T2(0), T17(0), C(0) ≥ 0 then the
solutions of the model (3.2.2) are non-negative for all time t ≥ 0.
Proof. Suppose the model has negative solutions, this implies that a time t0 < ∞ exists
which can be defined as
t0 =in f {t > 0
∣∣M1(t), M2(t), Nk(t), Tc(t), T0(t), T1(t), T2(t), T17(t), Pc(t), C(t) < 0
Assuming this relation, model Equation (3.2.2) can be integrated from time interval [t0, t]
to get the following solutions for
• Type 1 Macrophages
dM1
dt
= ϕ1T1Ci +
αm M1
(
1− M1βm
)
1+ pi1C
− (δmC + µm)M1
≥ −(δmC + µm)M1, for t ≤ t0.
Since M1(t0) ≥ 0 then the following unique positive solution exists,
M1(t) ≥ M1(t0) exp
(
−
∫ t
t0
(δmC + µm)ds
)
≥ 0 for t ∈ [t0 − e1, t0 + e1].
• Type 2 Macrophages
dM2
dt
≥ −µm M2, for t ≤ t0.
Since M2(t0) ≥ 0 then a unique positive solution exists as shown below,
M2(t) ≥ M2(t0) exp
( ∫ t
t0
−µmds
)
≥ 0 for t ∈ [t0 − e2, t0 + e2].
• Natural Killer cells
dNk
dt
≥ −Nk(δkC + µk), for t ≤ t0.
Since Nk(t0) ≥ 0 then a unique positive solution exists as shown below,
Nk(t) ≥ Nk(t0) exp
(
−
∫ t
t0
(δkC + µk)ds
)
≥ 0 for t ∈ [t0 − e3, t0 + e3].
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• CTLs
dTc
dt
≥ −Tc(δtC + µ8), for t ≤ t0.
Since Tc(t0) ≥ 0 then a unique positive solution exists as shown below,
Tc(t) ≥ Tc(t0) exp
(
−
∫ t
t0
(δtC + µ8)ds
)
≥ 0 for t ∈ [t0 − e4, t0 + e4].
• Naive T helper (Th0) cells
dT0
dt
≥ −T0(δtC + µt), for t ≤ t0.
Since T0(t0) ≥ 0 then a unique positive solution exists as shown below,
T0(t) ≥ T0(t0) exp
(
−
∫ t
t0
(δtC + µt)ds
)
≥ 0 for t ∈ [t0 − e5, t0 + e5].
• Type 1 T helper (Th1) cells
dT1
dt
≥ −T1(δtC + µt), for t ≤ t0.
Since T1(t0) ≥ 0 then a unique positive solution exists as shown below,
T1(t) ≥ T1(t0) exp
(
−
∫ t
t0
(δtC + µt)ds
)
≥ 0 for t ∈ [t0 − e6, t0 + e6].
• Type 2 T helper (Th2) cells
dT2
dt
≥ −µtT2, for t ≤ t0.
Since T2(t0) ≥ 0 then a unique positive solution exists as shown below,
T2(t) ≥ T2(t0) exp
(
−
∫ t
t0
(µt)ds
)
≥ 0 for t ∈ [t0 − e7, t0 + e7].
• Type 17 T helper (Th17) cells
dT17
dt
≥ −µtT17, for t ≤ t0.
Since T17(t0) ≥ 0 then a unique positive solution exists as shown below,
T17(t) ≥ T17(t0) exp
(
−
∫ t
t0
(µt)ds
)
≥ 0 for t ∈ [t0 − e8, t0 + e8].
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• Infected cells
dPc
dt
≥ −Pc(θI + µI +Λc (Tc + Nk) , for t ≤ t0.
Since Pc(t0) ≥ 0 then a unique positive solution exists as shown below,
Pc(t) ≥ Pc(t0) exp
(
−
∫ t
t0
(θI + µI +Λc (Tc + Nk) ds
)
≥ 0 for t ∈ [t0 − e9, t0 + e9].
• Tumour cells
dC
dt
≥ −C (µC +Λc(M1 + Nk + Tc + T1)
1+ pi2C
, for t ≤ t0.
Since C(t0) ≥ 0 then a unique positive solution exists as shown below,
C(t) ≥ C(t0) exp
(
−
∫ t
t0
µC +Λc(M1 + Nk + Tc + T1)
1+ pi2C
ds
)
≥ 0
for t ∈ [t0 − e10, t0 + e10].
The solutions of Equation (3.2.2) are non-negative for the time interval t ∈ [t0 −
e, t0 + e] with e = min{e1, e2, e3, e4, e5, e6, e7, e8, e9, e10}. Which contradicts with
the initial assumption on t0. Since the initial conditions and solutions to the model
are always positive, this implies that the model is biologically well posed and we
can draw meaningful findings from the analysis.
3.3.1 Steady state solutions
Steady states are solutions that are time invariant and they are often used to investigate
long-term behaviour of models. Because of the highly non-linear terms in the model,
we will only consider the tumour-free steady states (TFSS).
3.3.1.1 Tumour-free steady state
The TFSS can be categorized as either type 1 or 2 immune signal as shown below
1. Type-1 tumour-free (T1TF) steady state can be characterized by
(M∗1 , M
∗
2 , N
∗
k , T
∗
c , T
∗
0 , T
∗
1 , T
∗
2 , T
∗
17, C
∗, P∗c ) = (M∗1 , 0, N
∗
k , T
∗
c , T
∗
0 , T
∗
1 , 0, 0, 0, 0)
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Modelling cytokine-mediated tumour-immune cell dynamics 30
where
M∗1 =
βm
αm
(αm − µm) , N∗k =
βk
αk
(αk − µk) , T∗c =
βt
αt
(αt − µ8) , T∗0 =
βt
αt
(αt − µt)
T∗1 =
1
2αt
(
βt (αt − µt)± βt
√
(αt − µt) (αmαt + 4αmβmϕ3 − αmµt − 4βmµmϕ3)
)
This steady state can exist if the proliferation rate of cell i is greater than its decay
rate, that is, αi > µi. We consider the positive root for Th1 steady state T∗1 because
a negative root will not be biologically meaningful.
2. Type 2 tumour-free (T2TF) steady state can be characterized by
(M∗1 , M
∗
2 , N
∗
k , T
∗
c , T0, T
∗
1 , T
∗
2 , T
∗
17, C
∗, P∗c ) = (0, M∗2 , 0, 0, 0, 0, T∗2 , T∗17, 0, 0)
where
M∗2 =
βm
αm
(αm − µm) , T∗2 =
βt
αt
(αt − µt) , T∗17 =
βt
αt
(αt − µt)
The T2TF steady state exists only if the proliferation rate of cell i is greater than its
decay rate, αi > µi.
3.3.1.2 Local stability analysis of the tumour-free steady state
The next generation matrix (NGM) approach was used to compute the reproduction
number R0 and investigate stability of the TFSS [71] as shown in Equation (3.3.2). R0
can be defined as the average number of infected immune cells produced by a single
tumour cell.
R0 = ρ(FV−1) with F =
∂Fi
∂Xj
(X∗), V =
∂Vi
∂Xj
(X∗), 1 ≤ i, j ≤ m, (3.3.2)
where ρ is the spectral radius, X∗ is the tumour-free steady state of model (3.2.2), matrix
Fi represents the rate of appearance of new infections and Vi describes the difference
between transfer rates of cells into and out of any compartment i. The rate of change of
immune and tumour cells can be represented as dX/dt = (F − V)X. Instead of using
full vectors F and V , we only considered the infected/infective classes, cancer C and
infected pre-cancerous Pc cells since m = 2.
Theorem 3.3.3 (Local stability analysis). The tumour-free steady state is asymptotically stable
if R0 < 1 and unstable otherwise.
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Proof. Given the two infected classes, the rate of new infections is defined as
F =
(
(δm M1 + δkNk + δt(Tc + Nk))C
θI Pc
)
,
and difference between the transfer rates of the two classes as
V =
(
Pc (θI + µI +Λc(Tc + Nk))
−αCC
(
1− CβC
)
− θc M2C + Λc(Nk+M1+Tc+T1)C1+pi2C + µcC
)
.
DifferentiatingF and V with respect to the infected cells Pc and tumour C at the tumour-
free steady state X∗ gives
F =
(
0 M∗1δm + N
∗
k δk + δt
(
N∗k + T
∗
c
)
θI 0
)
,
which is a non-negative transmission matrix and,
V =
(
Λc
(
N∗k + T
∗
c
)
+ µI + θI 0
0 Λc
(
M∗1 + N
∗
k + T
∗
1 + T
∗
c
)−M∗2θc − αc + µc
)
,
the non-singular transition matrix. The inverse matrix of V can be given as
V−1 =
 1Λc(N∗k +T∗c )+µI+θI 0
0 1
Λc(M∗1+N∗k +T∗1 +T∗c )−M∗2θc−αc+µc
 .
The next generation matrix (NGM) is given by
FV−1 =
 0 M
∗
1δm+N
∗
k δk+δt(N∗k +T∗c )
Λc(M∗1+N∗k +T∗1 +T∗c )−M∗2θc−αc+µc
θI
Λc(N∗k +T∗c )+µI+θI
0
 . (3.3.3)
The reproduction number is the off-diagonals in Equation (3.3.3) which can be split into
two partial reproduction numbers, R01 for the infected and R02 for the tumour cells
R01 =
M∗1δm + N
∗
k δk + δt
(
N∗k + T
∗
c
)
Λc
(
M∗1 + N
∗
k + T
∗
1 + T∗c
)−M∗2θc − αc + µc and
R02 =
θI
Λc
(
N∗k + T∗c
)
+ µI + θI
.
The spectral radius is given as
ρ(FV−1) =
√
R0 =
√
R01R02. (3.3.4)
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3. Modelling cytokine-mediated tumour-immune cell dynamics 32
Theorem 2 proposed by Van den Driessche and Watmough [71], states that the TFSS is
locally asymptotically stable whenever R0 < 1 and unstable otherwise. When R0 < 1 it
means that on average, less than 1 normal (tumou-free) cell become cancerous for every
interaction it has with tumour cells. A combination of higher values in parameters, such
asΛc, µc, and µI , decreases the value of R0, whereas higher values in parameters, such as
δm, δk, δt, θc, and αc increases the value of R0. This makes sense because, higher values
in the inactivation rate Λc, and natural death rate µc of tumour cells and infected cell µI
increases the rate of necrosis and apoptosis of tumour and infected cells, this might lead
to a tumour-free steady state. It was inconclusive to say if the TFSS is stable R0 < 1 or
unstable R0 > 1.
3.3.1.3 Global stability of tumour-free steady state
Theorem discussed by Castillo-Chavez et al. [72] was used to investigate the global sta-
bility of the tumour-free steady state. Considering the components of vector X as the un-
infected class (immune cells) and vector Y as the infected class (infected (pre-cancerous)
and tumour cells). Then the system can be defined as
dX
dt
= F(X, Y), for all X ∈ Rn, and Y ∈ Rm,
dY
dt
= G(X, Y), with G(X, 0) = 0
Suppose V0 = (X∗, 0) is a tumour-free steady state of the model, then V0 is globally
asymptotically stable if
1. R0 < 1 ,
2. For dX/dt = F(X, 0), the TFSS X∗ is globally asymptotically stable and,
3. G(X, Y) = AY− Gˆ(X, Y), with Gˆ(X, Y) ≥ 0 for X, Y ∈ Ω. Where A = D′YG(X∗, 0)
is an n-matrix who’s off-diagonals are non-negative and Ω is a region where the
system is biologically meaningful.
It is worth noting that, in our case, the number of uninfected classes, n = 8 and the
number of infected classes, m = 2.
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Theorem 3.3.4. The tumour-free steady state of model (3.2.2) exists and is globally asymptoti-
cally stable if it satisfies the above conditions.
Proof. Assuming that the first assumption is met R0 < 1. The system
F(X, Y) =
(
dM1
dt
,
dM2
dt
,
dNk
dt
,
dTc
dt
,
dT0
dt
,
dT1
dt
,
dT2
dt
,
dT17
dt
)T
,
G(X, Y) =
(
dPc
dt
,
dC
dt
)T
,
=
(
(δm M1 + δkNk + δt(T0 + Tc + T1))C− Pc(θI + µI +Λc(Tc + Nk))
αCC
(
1− CβC
)
+ θI Pc + θc M2C− Λc(Nk+M1+Tc+T1)C1+pi2C − µcC
)
,
with
A =
(
−(θI + µI +Λc(Tc + Nk) M1δm + Nkδk + δt (T0 + T1 + Tc)
θI −Λc (M1 + Nk + T1 + Tc) + M2θc + αc − µc
)
.
Given that all the parameter values are always positive, it is easy to show that the off-
diagonals of matrix A = G(X∗, 0) are non-negative. Since the infected class Y = (Pc, C)T
then,
AY =
(
(δm M1 + δkNk + δt(T0 + T1 + Tc))C− Pc(θI + µI +Λc(Tc + Nk))
θI Pc −ΛcC (Nk + M1 + Tc + T1) + θc M2C + αcC− µcC
)
.
Gˆ(X, Y) is given as
Gˆ(X, Y) = AY− G(X, Y),
=
(
0
C
(
αcC
βc
+Λc (Nk + M1 + Tc + T1)
(
1
1+pi2C
− 1
)))
The term 11+pi2C − 1 is negative. Therefore, the TFSS V0(X∗, 0) will be globally asymptot-
ically stable when,
αcC
βc
+
Λc (Nk + M1 + Tc + T1)C
1+ pi2C
≥ Λc(Nk + M1 + Tc + T1)
because this will imply that Gˆ(X, Y) ≥ 0, and unstable otherwise.
The steady state of the TFSS cannot be obtained analytically due to the non linearity of
the model and numerical analysis is preferred. In the next section, we perform numeri-
cal simulations for model (3.2.2) using R version 3.4.3 (www.r-project.org).
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3.4 Numerical analysis
The non-linear IVP equations in Equation (3.2.2) cannot be integrated to find exact solu-
tions, we solved the system of equations numerically using deSolve package developed
by Soetaert et al. [73].
3.4.1 Parameter estimation
The innate immune cells are always present in the lymph nodes, but it takes a couple of
hours to days for the adaptive immune cells to become activate [12]. We assumed that
the infected and adaptive immune cells (CTLs, Th0, Th1, Th2 cells) were inactive and
absent at the initial time. Whereas cancer and innate immune cells were present, that
is approximately 0.1× 106 cancer cells, 2× 104 M1 macrophages, 104 M2 macrophages
and 104 NK cells were present at the initial time.
We estimated parameter values from experimental data published by Kuznetsov et al.
[56], Uhr et al. [65], Diefenbach et al. [70], Wilkie and Hahnfeldt [74], Ribeiro et al.
[75], Benzekry et al. [76]. In a case where a parameter had a wide range of values,
we chose the most appropriate values for the model or an average. For some of the
unobserved parameters, we estimated them by fitting the model in Equation (3.2.2) to
the average breast cancer volume data published by Benzekry et al. [76]. Where a total
of 5 experiments were conducted on 6- to 8-week-old 34 female mice to investigate tu-
mour growth [76]. Benzekry et al. [76] implanted approximately 1× 106 of LM2-4LUC+
cells originally derived from MDA-MD-231 cells (triple negative breast cancer cell line),
into the right inguinal mammary fat pads and measured the tumour volume (size) reg-
ularly from day 18 to 38. We used the least square method to estimate parameters by
minimizing the sum of squared differences/errors (SSE) between the data and model
output.
The parameter values shown in Table 3.3 were estimated as follows
• Death rate (day−1): Precursor macrophages in the lymph nodes have a half-life
of approximately 17.4 hours to 5 days [58], the NK cells and CD8+ T cells can
be depleted within 14-27 days [70], and the half-life of T lymphocytes from the
spleen has been approximated to be 30 days [56]. The formula, t1/2 = ln(2)/µi is
used to calculate the death rate where t1/2 describes the half-life of cells. There-
fore, using this formulae, macrophages, CTLs, and CD4+ T cells have a death
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rate of µm = (ln(2)/0.725, ln(2)/5) ≈ (0.725, 0.13), µ8 = (ln(2)/14, ln(2)/27) ≈
(0.0495, 0.0256) and µt = ln(2)/30 ≈ 0.023, respectively. We choose µm = 0.131,
µ8 = 0.034, µt = 0.023 and µk = 0.0412.
• Activation rate (day−1): According to de Pillis et al. [59] the maximum recruitment
rate of CD8+ T cells is 0.0375 and 0.025 day−1 for NK cells. We assumed that the
activation rate ϕ1 = 0.02 for the innate cells, ϕ2 = 0.0375 for CTLs and activated
naive T (Th0) cells, and ϕ3 = 0.024 for CD4+ T (Th1, Th2, Th17) cells.
• Intrinsic growth rate (day−1): The median breast cancer growth rate was αc =
0.502 for the 34 animals [76]. The intrinsic growth rate for immune cells was es-
timated from Kuznetsov et al. [56], Uhr et al. [65]. We choose αt = 0.22, αm =
0.2, αk = 0.22.
• Carrying capacity (cell−1): The average tumour volume for the 34 animals was
between a range of 202-1902 mm3 (1 mm3 = 1000 cells) [76]. The carrying capacity
for the immune cells was estimated from Kuznetsov et al. [56], Uhr et al. [65]. We
assumed βk = 2.02× 109, βt = 109, βc = 109 and βm = 109.
• Inactivation rate (cell−1 day−1): Tumour cells can be killed by M1 macrophages at
a rate 10−6 and 5.3× 10−8 by CD4 T cells [58]. NK cells are killed by tumour cells
at a rate δk = 3.5× 10−6 [70]. We assumed δm = 10−6, δt = 10−7 and Λc = 10−5.
• Unobserved parameter values, such as θI , θc, µc, µI ,pi0,pi1,pi2 were estimated by
fitting the model in Equation (3.2.2) to average data provided by [76], as shown in
Figure 3.2.
Table 3.3 provides a summary of the parameter values used for numerical analysis.
3.4.2 Numerical solutions
The system in Equation (3.2.2) was solved numerically using the baseline parameter
values shown in Table 3.3 and initial conditions stated above. The results are shown in
Figure 3.3.
According to Figure 3.3 type 1 immune signals (M1 macrophages, NK cells, CTLs, Th0
and Th1 cells) managed to control the proliferation of type 2 immune signals (Th2, Th17
cells, M2 macrophages) and tumour cells for the first 10 days, after which type 2 immune
signals over-powered type 1 immune signals and continued to proliferate for some time.
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Table 3.3: Parameter values
Parameter Baseline value Units Source
ϕ1 0.02 day−1 [58]
ϕ2 0.0375 day−1 [59]
ϕ3 0.024 day−1 [56]
pi0 0.021 day−1 [76]∗∗
pi1 0.021 day−1 [76]∗∗
pi2 0.0231 day−1 [76]∗∗
αm 0.2 day−1 [74]∗
αk 0.22 day−1 [74]
αt 0.22 day−1 [74]
αc 0.502 day−1 [76]
βm 1× 109 cell−1 [65]∗
βk 2.02× 109 cell−1 [56][65]
βt 1×109 cell−1 [65]∗
βc 1× 109 cell−1 [56, 65, 76]
δm 1× 10−6 cell−1 day−1 [70]∗
δk 3.5×10−6 cell−1 day−1 [70]
δt 1×10−7 cell−1 day−1 [58, 65, 77]
µk 0.0412 day−1 [59]
µm 0.131 day−1 [58]
µ8 0.034 day−1 [70, 75]
µt 0.023 day−1 [56]
µI 0.0272 day−1 [76]∗∗
µc 0.0115 day−1 [76]∗∗
κ 103 cell [60]
Λc 1×10−5 day−1 cell−1 [58]
θc 4.5117×10−12 day−1 cell−1 [76]∗∗
θI 1×10−4 day−1 cell−1 [76]∗∗
ξ1 3.72× 10−5 pg/cell/day [78]
ξ2 1.5× 10−5 pg/cell/day [78]
∗∗ estimated values from experimental data [76]
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Figure 3.2: The best fit curve used to estimate unobserved parameter values from data
published by Benzekry et al. [76].
Tumour cells reached a dormant steady state during this phase. These findings are sim-
ilar with the findings of den Breems and Eftimie [58], Diefenbach et al. [70], but they ob-
served that CTLs were depleted after 20 days. Panel (b-c) of Figure 3.3 indicate that M1
macrophages, NK and Th1 cells stimulate each other. The decrease in M2 macrophage
cell density might have been as a result of the decrease in Th2 cell population as shown
in panel (a) of Figure 3.3. This observation shows that the continuous proliferation of
tumour cells is highly dependent on tumour-promoting cytokines, such as IL-4, IL-6,
IL-10, IL-13, and IL-23 secreted predominantly by type 2 immune signals. Figure 3.4
visualizes the rate of change of these cytokines on day 5, 10, 15 and 40.
Numerical results in Figure 3.4 emphasized the role of cytokines in activating an im-
mune response and promoting tumour progression [12]. The depletion of type 1 cy-
tokines 3.4 lead to a decrease in type 1 immune cells efficiency, cytotoxicity and popu-
lation, this fallout promoted tumour development as shown in panel (a) of Figure 3.3.
IL-10, IL-23 and TGF-β dominated from day 25, a time when type 1 signals had been
depleted. Furthermore, we analysed the effect of IL-23 and TGF-β on the population of
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Figure 3.3: Panel (a-b) shows the positive effect type 2 immune signals (M2
macrophages, Th2 and Th17 cells) has on tumour cells. The depletion of type 1 im-
mune signals (M1 macrophages, CTLS, NK, Th0, Th1 cells) on day 10 resulted in the
proliferation and progression of tumour cells. The population of precancerous cells in
Panel (e) are proportional to the population of type 1 immune signals. Panel (f) shows
the cell dynamics in panel (a-e) on a logarithmic x− and y− axis scale.
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Figure 3.4: Anti-inflammatory cytokines, such as IL-4 (I4), IL-6 (I6), IL-10 (I10), IL-23
(I23)and TGF-β (Iβ) dominate from day 15 after the pro-inflammatory cytokines, such as
TNF-α (Iα) and IFN-γ (Iγ) were depleted.
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tumour and immune cells as shown in Figure 3.5.
Figure 3.5: Panel (a) indicates that the removal of IL-23 has no effect on tumour cell
population. However, the removal of TGF-β results in tumour clearance but, this caused
an over-stimulation of immune cells.
The absence of TGF-β resulted in the elimination of tumour cells by day 4. We noticed
that by day 7, all the immune cells had exceeded the carrying capacity of 1010 cells,
this can cause a series of serious dysfunctional organs [14]. Similar results were also
obtained by Kirschner and Panetta [61]. This finding illustrate the crucial role of TGF-
β in controlling and regulating explosive proliferation of immune cells [14]. Arciero
et al. [36] observed that TGF-β inhibited IL-2 production, reduced antigen expression,
activation of immune effector cells and tumour detection by effector cells. Limited anti-
inflammatory signals can lead to increased cytotoxicity and tumour regression. This
might explain why the tumour cells in this study was not cleared.
Mathematical models solemnly depend on parameter values. A change in parameter
values can make a lot of difference in the model output. Sensitivity analysis measures
the change in a mathematical model output associated with small perturbations in the
model input parameters. We performed sensitivity analysis to determine parameters
that influence the output of model (3.2.2).
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3.4.3 Sensitivity analysis
Sensitivity analysis measures the change in a mathematical model output associated
with small perturbations in the model input parameters. We used the Flexible Modelling
Environment (FME) package developed by Soetaert and Petzoldt [79] to determine the
important parameters in model (3.2.2). The method used generated sensitivity functions
for all variables in model (3.2.2). A summary of these sensitivity functions revealed
that the (i) immune cell activation rate ϕ1, ϕ2, ϕ3, (ii) inhibition rate pi1, pi2, (iii) half
saturation constant κ, (iv) CTLs and T helper cell intrinsic growth rate αt, (v) CTLs death
rate µ8, and T helper cells µt, and (vi) the carrying capacity of CTLs and T helper cells
βt were more sensitive on the output variables in model (3.2.2).
Some of the unobserved parameters including pi1,pi2 were identified as the most sensi-
tive parameters and others including µI , µc, and θI were involved in the reproduction
number R0 in Equation (3.3.4). We performed global sensitivity analysis to explore the
effect of varying these unobserved parameters on tumour cell population as shown in
Figure 3.6.
Figure 3.6: Global sensitivity analysis involved varying some the unobserved param-
eters pi1, pi2, µI , µc, θI by 40% from the baseline values in Table 3.3. These parameters
had a negligible effect on tumour cell population.
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Figure 3.6 indicates that the perturbations of the unobserved parameters made a neg-
ligible difference in the output of tumour cells. Parameter µc representing the natural
death rate for tumour cells had more effect on the global sensitivity outcome compared
to the other unobserved parameters.
To determine conditions necessary for tumour clearance, we varied the intrinsic growth
rate αc. This parameter can be varied experimentally by including treatment or con-
verting the local tumour environment to be unfavourable to tumour progression, for
example, by increasing tumour-suppressing cytokines (IL-2, IFN-γ) in the local tumour
site. Figure 3.7 shows the local sensitivity analysis of αc.
Figure 3.7: Local sensitivity analysis of the intrinsic growth rate αc by decreasing it by
15% (Panel a) and 25% (Panel b) from its baseline value of 0.502.
The tumour intrinsic growth rate αc was varied over a range of 15% − 25% from its
baseline value of 0.502. Decreasing the intrinsic growth rate by 15% (0.425) resulted in
a 60% decrease of the population of tumour cells by day 20 as shown in Panel (a) of
Figure 3.7. Decreasing intrinsic growth rate by 25% (0.375) resulted in tumour clearance
by day 11 as shown in Panel (b) of Figure 3.7.
From the numerical analysis, we observed that the quality and effectiveness of an im-
mune response relies on the interactions between cytokines produced and the host im-
mune cells [12]. The activation of an immune cell alters its gene expression. Since, we
are entering an era for cell-based and gene-based therapies, it is important to study the
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genes that regulate cytokine production. The next chapter covers analyses RNA-Seq
data to identify DEGs, pathways and biological processes that can be used to explain
breast cancer disease.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4
Expression level based
cytokine-regulator gene prediction
4.1 Introduction
Gene expression data sets can be analysed in two ways: a gene-based approach where
genes play the role of features or sample-based approach where samples play the role
of features. We used a gene-based approach to analyse RNA-Seq breast cancer data set.
Since high RNA-Seq data can be very noisy, we applied the Miller’s test to filter out
genes with high variation. The significance analysis of micro-arrays (SAM) approach
was applied to the filtered data set to predict differentially expressed genes (DEGs)
across breast cancer (tumour) and healthy (tumour-free) samples. A selected gene set
containing DEGs was used to predict enriched pathways and biological processes asso-
ciated with breast cancer. In the next sections, we perform pre-processing and statistical
analysis of the gene expression data.
4.2 Data retrieval and pre-processing
RNA-Seq techniques based on next generation sequencing (NGS) technologies are used
for gene expression profiling. A sequencer uses image analysis on micro-array chips to
measure individual gene expression at high resolution [40]. The sequencing machine
generates a list of reads (millions of short strings) from random positions of each sam-
ple (input RNAs). Each read in the list can be computationally mapped on a reference
genome, to a particular gene, to reveal a transcriptional map. A count is made for the
44
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number of reads mapped to each particular gene, this represents its level of expres-
sion [39, 40].
Gene expression data sets can be obtained from The Cancer Genome Atlas (TCGA)
(https://cancergenome.nih.gov/) project which contains harmonized genomic data
sets for over 20 types of cancer. For the purpose of this study, analysis-ready breast
cancer gene expression data set was downloaded from GDAC Firehose and FireBrowse
(http://gdac.broadinstitute.org/). Gene expression data sets are represented by a
large matrix with gene expression levels (count data) over a number of RNA-Seq exper-
iments (samples) and usually, the genes measured are more compared to the number
of samples. Suppose n experiments (samples) were performed on p regions of interest
(genes). Let Xij be the expression level of gene i in sample j under condition 1, Yik be
the expression level of gene i in sample k under condition 2 and the response variable
z = {1, 2} represents the two conditions, that is the tumour and tumour-free samples,
respectively. We preferred to work with the transposed matrix and denote the n × p
matrix as G, which can be formalized as a numerical vector
G =
[
Xij
Yij
]
16i6p, 16j6n1, 16k6n2
where n1 is the tumour sample size, n2 is the tumour-free sample. Figure 4.1 illustrates
the untransposed p× n matrix.
RNA-Seq experiments result in large data sets containing a long list of genes and their
respective expression levels. The downloaded breast cancer data set contained 20,531
genes from 1,100 tumour samples and 112 tumour-free samples. The data had been
normalized using the upper-quartile (UQ) normalization approach given as
Normalized count =
raw count values× 100
75thpercentile of the column (gene) i
.
The UQ approach removes the bias highly expressed genes have over lowly expressed
genes without introducing additional noise. One could use the median for normal-
ization but due to preponderance of low-count genes, that statistic will be biased and
uninformative for DEGs thus, the UQ approach was preferred. Normalized RNA-Seq
data are highly skewed and noisy, assuming that the gene expression data follows a
log-normal distribution, it is therefore reasonable to transform the data to reduce the
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Figure 4.1: RNA-Seq experiments normally result in a large data set containing a long
list of genes. The downloaded gene expression data set can be represented as a G matrix
with p genes and n samples and their respective expression levels Xij and Yij represent-
ing tumour and tumour-free samples, respectively.
variability across samples
transformed data = log2(normalized count+ 1),
a value of 1 is added to the normalized counts to offset it from zero and to avoid missing
values or large variances (Infs/-Infs). The transformed data for tumour samples Xij and
the tumour-free samples Yik have a geometric mean and standard deviation defined as
x¯i =
n1
∑
j
xij
n1
=
n1
∑
j
log2(Xij + 1)
n1
and s1 =
√√√√√ n1∑j (xij − x¯i)2
n1 − 1 for tumour samples and
y¯i =
n2
∑
k
yik
n2
=
n2
∑
k
log2(Yik + 1)
n2
and s2 =
√√√√√ n2∑k (yik − y¯i)2
n2 − 1 for tumour-free samples.
Geometric mean is approximately equal to the median and as an estimate of the popula-
tion mean, it is less likely to be affected by extremely large values compared to the arith-
metic mean. P-values obtained in logarithmic scale remain valid in original scale [80].
Since RNA-Seq experiments involve a multi-step process, there is a potential of biologi-
cal, experimental/technical and residual variation [40]. It is therefore necessary to filter
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genes with high variations, that is genes with low counts before performing the actual
statistical analysis. Filtering genes with high variation will reduce the dimensionality of
the data set given that the data set has more genes/features compared to sample size.
Normally distributed data sets have a mean µ and variance σ2. The standard deviation
is not an appropriate measure of dispersion in this study, because the gene expression
mean values across the samples are not identical [81]. The coefficient of variation (CV),
a unit-free measure of dispersion [82], was used for quantifying heterogeneity of gene
expression levels across the two samples. The population CV defined as γ = σ/µ mea-
sures the variability of a population relative to its mean and standard deviation. When
the distribution is unknown, the CV can be estimated from observed gene expression
data as γˆ = si/|x¯i| and γˆ = si/|y¯i| for tumour and tumour-free samples, respectively.
To investigate whether a gene can be considered for further analyses (gene with γˆ < 1),
we set the following hypothesis
H0 : γˆ < 1 versus HA : γˆ > 1. (4.2.1)
Statistical tests such as Wald, Miller, or likelihood ratio are used to test the significance
of the differences and verify that the differences are not by random chance. We used
Miller’s test which has a Gaussian distribution Z∼N(0, 1) with a mean equal to 0 and
variance equal to 1 as described in Equation (4.2.2).
MiL =
γˆ− γ0
sm
∼Z(0, 1) where sm =
√
γˆ4 − 0.5γˆ2
n
and γ0 = 1. (4.2.2)
The CV of each gene in the data set was computed, and genes across the samples with
high variation that were less likely to be interesting were removed at a level of signifi-
cance α < 0.05. Removing genes with high variation reduced the dimension of the data
set by approximately 19%. Figure 4.2 illustrates the influence of lowly expressed genes.
The sharp curve in panel (a) of Figure 4.2 indicates the presence of genes with low counts
that should be filtered out before performing the actual statistical analysis. In the next
section we predict DEGs by applying the significance analysis of micro-arrays (SAM)
approach.
4.3 Statistical analysis of breast cancer gene expression data
It is expected that most genes across the tumour and tumour-free samples are normally
expressed and only a few are differentially expressed. A gene is identified as differ-
entially expressed if its expression level of transcripts (counts) between two or more
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Figure 4.2: Panel (a) and (b) represents standard deviation against expression level mean
value plots before and after Miller’s test, respectively. The sharp curve (red line) in Panel
(a) indicates the presence of genes with low counts.
conditions is different. Statistical methods used to detect DEGs can be grouped into
two (i) parametric methods used when the distribution is known, such as t-test and
its variations, empirical Bayes methods, and (ii) non-parametric methods used when
the distribution is unknown, such as Mann-Whitney test, Wilcoxon signed-rank test,
Kruskal-Wallis test, and non-empirical Bayes method. Useful approaches have been pro-
posed for individual-based gene analyses, both Seyednasrollah et al. [83] and Rapaport
et al. [41] have compared various statistical algorithms and they noted that array-based
methods adapted to RNA-Seq data performed well compared to the methods developed
for analysing RNA-Seq data. A non-parametric SAM-permutation based approach was
found to detect a relatively large number of DEGs Chu et al. [84]
4.3.1 The SAM approach
For each gene, we conducted a SAM permutation-based approach to identify DEGs.
Each gene is considered independently when performing the statistical analysis, the test
is used to detect the significance of any observed differences between the two samples.
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We used the following steps to compute the SAM di statistic as proposed by Tibshirani
et al. [85].
1. For each gene i = 1, 2, . . . , p the following statistic was computed
di =
r(i)
s(i) + s0
, with r(i) = x¯i − y¯i, s(i) = sp
√
1
n1
+
1
n2
and
sp =
√√√√√ n2∑k (xij − x¯i)2 + n1∑j (yik − y¯i)2
n1 + n2 − 2 , (4.3.1)
where xij is the expression level for gene i in tumour sample j, yik is the expression
level for gene i in tumour-free sample k, x¯i is the expression level mean for gene i
for tumour samples and y¯i is the expression level mean for gene i for tumour-free
samples, s(i) is the gene-specifier scatter, sp is a pooled standard deviation, and
the parameter s0 is a non-negative exchangeability factor.
2. Order the di statistic based on the statistical significance of the observed differences
between the two groups such that d(1) 6 d(2) 6 . . . 6 d(p).
3. Perform 10,000 sets of permutations on the sample labels (tumour and tumour-
free). For each permutation, re-calculate steps (i)-(ii). The estimated expected null
score for each permutation b was given as
Expected d(i) = d¯(i) =
B
∑
b=1
db(i)
B
, where B = 10, 000.
4. Plot the ordered observed di scores against the expected di null scores.
5. Pick a threshold/cut-off ∆ to identify genes expressed differently across the two
conditions. A gene is significant if∣∣di − d¯i∣∣ > ∆,
where di is the observed null score and d¯i is the expected null score calculated from
step (iii).
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4.3.2 Identification of differentially expressed genes
The exchangeability factor s0 was used to minimize the coefficient of variation of di.
Parameter s0 was estimated from pooling expression data of all the genes. Using an s0
equal to 0.0208, the observed di and expected di null score for each gene i was computed.
Our interest is to find significant genes that are differently expressed between the two
samples. We selected DEGs genes with a p-value < 0.05 using both the SAM T-statistic
and the SAM permutation-based statistic. These genes were above a fixed threshold
∆ = 8.1538, the upper quartile of |di − d¯i|. The p-values obtained gives confidence that
the same association will be found for a new sample with that particular phenotype or
expression profile. The DEGs (in pink) and non-DEGs (in black) can be visualized as
shown in Figure 4.3.
Figure 4.3: The SAM approach was used to detect 4,159 differentially expressed genes
(DEGs). The plot shows non-DEGs (in black circles) and DEGs (in pink circles).
A total of 4,159 genes were identified as differentially expressed. These genes con-
stitute about 20% of the original data set. Out of the 4,159 genes, 2,816 genes were
over-expressed and 1,343 genes were under-expressed in tumour samples whereas 3,022
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genes were over-expressed and 1,137 genes were under-expressed among tumour-free
samples. Figure 4.4 shows a density distribution and box plot to examine any differences
in the 4,159 DEGs across tumour and tumour-free samples
Figure 4.4: Slight differences in the 4,159 differentially expressed genes across samples
that are with tumour (WT) and tumour-free(TF).
There is a very slight difference in the expression level means of the 4,159 DEGs across
the two samples. Some of the DEGs in Figure 4.4 can be used to identify bio-marker
genes that explain phenotypic differences between two conditions. Our interest is to
find genes that are common and expressed differently between the two samples that are
either over-expressed or under-expressed. Therefore, it will be reasonable to reduce the
gene set of interest to a small number of genes that can be used as marker genes for
breast cancer detection.
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4.3.2.1 Identification of breast cancer marker genes
The ability to successfully distinguish between samples using gene expression data is
an important aspect of bio-marker discovery. Genes that are either active or inactive
and expressed differently across breast cancer and tumour-free samples can be used
to characterise the disease. A re-sampling method was used to identify odd-shared
common DEGs across tumour and tumour-free samples. A total of 298 over-expressed
genes in tumour samples were under-expressed in tumour-free samples and 504 under-
expressed genes in tumour samples were over-expressed in tumour-free samples. Since
we are interested in keeping genes that might be of interest as small as possible, we
selected 40 genes which might explain the phenotypic differences between tumour and
tumour-free samples. Table 4.1 and 4.2 lists the gene set of interest with description
terms obtained from the UniProt knowledgebase database (http://www.uniprot.org).
There is a clear difference in expression level means across tumour and tumour-free sam-
ples as shown in Table 4.1 and Table 4.2. The expression level mean values for the over-
expressed genes in tumour samples were higher compared to the under-expressed genes
in tumour-free samples. The expression level mean values for the under-expressed
genes in tumour samples were lower compared to the over-expressed genes in tumour-
free samples. We used a density distribution and box plot to further examine the differ-
ences in the selected gene set as shown in Figure 4.5.
There is a difference in the expression level mean values across tumour and tumour-
free samples for the selected gene set in Table 4.1 and 4.2. WTOE genes have a higher
expression level mean compared to TFUE, WTUE and TFOE. Although, random genes
can be identified as differentially expressed, we can expect that some of the selected
genes in Table 4.1 and 4.2 are associated with the phenotypic differences between the
two samples. Furthermore, the hierarchical clustering plot (heatmap) in Figure 4.6 gives
a visualization of the patterns in the selected list of DEGs across the two samples.
The heatmap in Figure 4.6 supports the suspicion that two clusters exist. The over-
expressed genes (in pink row names) clustered into two groups, with the tumour sam-
ples having higher expression levels compared to tumour-free samples. The under-
expressed genes (in black row names) clustered into two groups, with tumour-free sam-
ples having higher expression levels compared to tumour samples. It is possible that
some of the genes in Table 4.1 and 4.2 can be used as marker genes for breast cancer
detection, classification and targets for treatment. One of the main goals of analysing
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Table 4.1: Top 20 over-expressed genes in tumour (WT) samples that were under-
expressed in tumour-free (TF) samples.
Protein Mean 95% Confidence Interval
ID name WT TF WT TF
ANLN Anillin 9.32 5.99 9.2447–9.4058 5.75901–6.216
ASF1B Histone chaperone
ASF1B
8.87 5.84 8.80477–8.92742 5.64039–6.03701
ASPM Abnormal spindle-
like microcephaly-
associated protein
8.86 5.16 8.77988–8.94681 4.88994–5.43269
C19orf21 Mitotic interactor
and substrate of
PLK1
8.84 5.62 8.71199–8.97698 5.26192–6.0021
CDC20 Cell division cycle
protein 20 homolog
9.04 5.58 8.9544–9.12285 5.33165–5.83411
COL10A1 Collagen alpha-
1(X) chain
10.56 3.78 10.43949–10.68534 3.53817–4.01912
COL11A1 Collagen alpha-
1(XI) chain
10.62 4.77 10.46703–10.76848 4.4818–5.05414
COMP Cartilage
oligomeric ma-
trix protein
10.35 5.57 10.22631–10.48075 5.18387–5.97755
DTL Denticleless pro-
tein homolog
8.93 5.85 8.86027–8.9939 5.624–6.06788
EEF1A2 Elongation factor
1-alpha 2
8.94 6.30 8.75738–9.13237 5.86191–6.74585
FOXM1 Forkhead box pro-
tein M1
9.60 6.15 9.52051–9.68584 5.92631–6.37061
GJB2 Gap junction beta-2
protein
8.90 5.15 8.7825–9.01485 4.92367–5.36686
IQGAP3 Ras GTPase-
activating-like
protein IQGAP3
9.12 5.10 9.04288–9.19718 4.84876–5.35248
KIF23 Kinesin-like pro-
tein KIF23
8.82 6.18 8.75628–8.88539 5.98043–6.37748
KIFC1 Kinesin-like pro-
tein KIFC1
9.05 5.93 8.98354–9.12346 5.71193–6.15298
MYBL2 Myb-related pro-
tein B
9.36 5.62 9.25767–9.46516 5.34726–5.88712
NUSAP1 Nucleolar and
spindle-associated
protein 1
9.53 6.40 9.46109–9.59094 6.18072–6.61277
PLK1 Serine/threonine-
protein kinase
PLK1
8.82 5.32 8.73789–8.89456 5.11399–5.51372
RRM2 Ribonucleoside-
diphosphate re-
ductase subunit
M2
9.68 6.14 9.60533–9.76053 5.86555–6.4105
UBE2C Ubiquitin-
conjugating en-
zyme E2 C
8.99 4.77 8.89906–9.07478 4.49894–5.04416
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Table 4.2: Top 20 under-expressed genes in tumour (WT) samples that were over-
expressed in tumour-free (TF) samples.
Protein Mean 95% Confidence Interval
ID name WT TF WT TF
ACADL Long-chain specific
acyl-CoA dehydroge-
nase, mitochondrial
2.77 6.96 2.64042–2.89347 6.63677–7.27304
AQPEP Aminopeptidase Q 2.65 7.12 2.5608–2.73286 6.68181–7.55625
CLDN19 Claudin-19 2.95 6.79 2.82596–3.07339 6.42963–7.1861
DEFB132 Beta-defensin 132 2.93 6.56 2.81696–3.03227 6.08507–7.0255
FAM196B Protein FAM196B 2.92 7.02 2.80996–3.01877 6.64757–7.40501
FGFBP2 Fibroblast growth
factor-binding pro-
tein 2
2.94 6.55 2.82017–3.04667 6.17551-6.91063
FIGF Vascular endothelial
growth factor D
3.15 9.19 3.03902–3.25991 9.00798–9.37411
GRIA4 Glutamate receptor 4 3.01 7.21 2.8798–3.13604 6.80405–7.63982
HIF3A Hypoxia-inducible
factor 3-alpha
2.99 7.88 2.88013–3.10529 7.67081–8.07789
HSD17B13 17-beta-
hydroxysteroid
dehydrogenase 13
1.89 6.54 1.81435–1.96978 6.1628–6.91454
KCNB1 Potassium voltage-
gated channel sub-
family B member1
2.95 6.70 2.84455–3.05093 6.46077–6.94607
KY Kyphoscoliosis pepti-
dase
2.81 6.71 2.70017–2.90674 6.37727–7.06032
LRRC2 Leucine-rich repeat-
containing protein
2
3.17 6.50 3.09608–3.25162 6.30511–6.68414
MASP1 Mannan-binding
lectin serine protease
1
2.64 6.71 2.53572–2.7319 6.45511–6.97115
NRG2 Pro-neuregulin-2,
membrane-bound
isoform
2.96 6.52 2.84606–3.0735 6.34775–6.68827
PFKFB1 6-phosphofructo-
2-kinase/fructose-
2,6-bisphosphatase
1
3.21 6.71 3.11716–3.30299 6.32161–7.10695
SCN3A Sodium channel pro-
tein type 3 subunit al-
pha
3.21 6.96 3.11047–3.30684 6.77919–7.15352
SLC7A10 Asc-type amino acid
transporter 1
2.80 7.25 2.6886–2.92001 6.76915–7.73683
TNMD Tenomodulin 2.55 7.15 2.42869–2.66261 6.83969–7.46191
TSLP Thymic stromal lym-
phopoietin
2.72 6.52 2.63166–2.80915 6.41222–6.62226
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Figure 4.5: The gene set in Table 4.1 and Table 4.2 had over-expressed genes in tumour
samples (WTOE) that were under-expressed in tumour-free samples (TFUE) and under-
expressed genes in tumour samples (WTUE) that were over-expressed in tumour-free
samples (WTUE). Over-expressed genes in tumour samples have a higher expression
level mean compared to the other categories.
gene expression data is to determine pathways and biological processes of interesting
gene sets associated with a disease outcome. Instead of focussing on individual genes,
we performed enrichment and pathway analysis on the selected gene sets in Table 4.1
and Table 4.2 in the next sections.
4.4 Gene set enrichment and pathway analysis
Annotation databases like Gene Ontology (GO) [43], Gene Ontology Annotation [44]
(GOA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) [45] are used to in-
terpret interesting DEGs. GO contains evidence-based annotations and biological de-
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Figure 4.6: The heat map indicates the presence of two distinct clusters across the tu-
mour and tumour-free samples in the selected gene sets.
scriptions of individual gene products (proteins) [43]. The domains of GO include bi-
ological processes, molecular functions or cellular components [43]. In this study, we
focus on predicting enriched biological processes of the selected gene set. KEGG is a
knowledge-base that maps a set of DEGs with biological functional information or in-
teracting molecules in a cells [45].
Enrichment and pathway analysis uses statistical methods to determine enriched bio-
logical processes and significant pathways associated with the outcome of a disease [42].
Hyper-geometric, Fisher’s exact, χ2 test and Jaccard index are used to perform enrich-
ment and pathway analysis. In this study, a hyper-geometric test was used because it
appropriately models the probability that a certain annotation term occurs i times in the
list of DEGs. The p-values obtained were corrected using the Bonferroni method. The
adjusted p-values was used to determine the probability of observing at least i number
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of genes out of the total gene list annotated to a particular term, given the proportion
of genes in the whole genome that are annotated to that term. A pathway or biological
process was said to be enriched at a significance level 0.05.
4.4.1 Enriched biological processes associated with breast cancer
Several GO similarity measures have been proposed. We applied a topology-based sim-
ilarity measure proposed by Mazandu and Mulder [86] to predict biological processes
over-presented in the selected gene set mapped from 17,292 GO human biological pro-
cesses. Level is a term in the GO directed acyclic graph. Unfortunately, the under-
expressed genes in tumour samples in Table 4.2 that were over-expressed in tumour-
free samples had no enriched biological processes. The over-expressed genes in tumour
samples that were under-expressed in tumour-free samples in Table Table 4.1 were as-
sociated with the enriched biological processes in Table 4.3.
Table 4.3: Enriched biological processes over-represented in tumour samples.
GO ID GO names Level p-value Adjusted p-value
GO:0000281 mitotic cytokinesis 7 0.0 0.0
GO:0007076 mitotic chromosome condensa-
tion
8 0.0 0.0013
GO:0051437 positive regulation of ubiquitin-
protein ligase activity involved
in regulation of mitotic cell cycle
transition
13 0.0002 0.0209
GO:0042787 protein ubiquitination involved
in ubiquitin-dependent protein
catabolic process
10 0.0003 0.0423
The enriched BPs are associated with cell division, differentiation and cell cycle progres-
sion. GO:0000281 (mitotic cytokinesis), is the physical separation of two daughter cells
during cell division, and CDC20 which is over-expressed in tumour samples plays a
central role in this biological process [87]. Studies have indicated that the failure to com-
plete cytokinesis can promote tumorigenesis and chromosomal/genome instability [87].
GO:0007076 (mitotic chromosome condensation), contributes to the pathogenesis of can-
cer and is a necessary process that prevents chromosomes from being entangled during
chromosome segregation [88]. Conjugation of ubiquitin to a substrate is performed by a
three-step process; ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2),
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and ubiquiting ligase (E3) [45, 89]. Ubiquitin system is responsible for processing MHC
I antigens and altered function/mutation of ubiquitin-proteosome especially E3 process
(ubiquitin ligase) can directly or indirectly lead to the onset of cancer [89, 90]. Known
genes involved in ubiquitin pathway include UBE2C for E2 process, BRCA1 and p53 for
E3 process [90]. p53 is a known tumour suppressor protein often found to be mutated
or depleted in breast cancer and is responsible for chromosomal instability [87, 91].
Hierarchical clustering was used to visualize the patterns of the biological processes
associated with breast cancer genes in Table 4.1 and 4.2. The hierarchical structure of
biological processes of the selected gene list is shown in Figure 4.7.
Figure 4.7: The biological processes in red represent the over-expressed genes in tumour
samples and the ones in blue represent under-expressed genes in tumour samples.
Most biological processes of the over-expressed genes in tumour samples that were
under-expressed in tumour-free samples in Table 4.1 clustered together (in red) and
biological processes of the under-expressed genes in tumour samples that were over-
expressed in tumour-free samples in Table 4.2 clustered together (in blue), except for a
few. The diagram shows groups of biological processes in breast cancer that might be
working together to promote its development and progression. In the next section, we
predicted pathways associated with the DEG set.
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4.4.2 Significant pathways associated with breast cancer
A pathway is a series of biological events occurring sequentially to maintain or change
cell environment for its stability. Pathways with a Bonferroni-adjusted p-value < 0.05
were selected as significant. The closer the p-value is to zero, the less likely it is for
the observed annotation to a group of genes to occur by random chance. Table 4.4 lists
significant KEGG pathways associated with the genes in Table 4.1 which were over-
expressed genes in tumour samples and under-expressed in tumour-free samples.
Table 4.4: KEGG pathways over-represented in tumour samples.
Pathway ID Pathway name Protein name P-value Adjusted p-value
hsa04218 Cellular senes-
cence
Forkhead box pro-
tein M1 (FOXM1),
Myb-related pro-
tein B (MYBL2)
0.0 0.0001
hsa04974 Protein digestion
and absorption
Collagen alpha-1
(X) and (XI) chain
(COL10A1 and
COL11A1)
0.0007 0.0163
Cellular senescence and protein digestion and absorption are the most significant KEGG
pathways associated with the over-expressed genes in breast cancer patients. Normally,
cell replication occurs till death however, some cells may stop multiplying and reach a
terminal cell proliferation arrest which can be triggered by an uncontrolled multiple cell
division, un-repaired DNA damage or cellular stresses, such as oncogenes [92]. These
naturally occurring senescent cells that accumulate with age can create an environment
that encourages tumour growth. Studies have shown that senescence cells in human
epidermal growth factor receptor 2 (HER2)-positive breast cancer cell lines, secrete IL-
6, IL-8 and other cytokines that promote tumour development and proliferation [92].
FOXM1 and MYBL2 involved in the cellular senescence pathway are proto-oncogenes
that code for proteins which regulate cell growth, differentiation and cell cycle progres-
sion. MYBL2 and FOXM1 can be used as a marker for cellular senescence and COL10A1,
and COL11A1 for protein digestion and absorption.
Table 4.5 lists significant KEGG pathways associated with genes in Table 4.2 which were
under-expressed genes in tumour samples and over-expressed in tumour-free samples.
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Table 4.5: KEGG pathways over-represented in tumour-free samples.
Pathway ID Pathway name Protein name P-value Adjusted p-value
hsa05150 Staphylococcus
aureus infection
Mannan-binding
lectin serine pro-
tease (MASP1)
0.0 0.0002
hsa04610 Complement
and coagulation
cascades
Mannan-binding
lectin serine pro-
tease (MASP1)
0.0 0.0006
hsa05033 Nicotine addiction Glutamate recep-
tor (GRIA4)
0.0016 0.0476
Staphylococcus aureus infection, nicotine addiction, and complement and coagulation
cascades were the most significant pathways associated with under-expressed genes in
tumour samples which were over-expressed in tumour-free samples. The compliment
system is an immune surveillance system and a mediator of the innate and adaptive im-
munity, and the coagulation cascade is responsible for ensuring homoeostatic mainte-
nance [45, 68, 93]. The experiment by Bianco et al. [93] found that the rapid proliferation
of macrophages can be induced by the activation of the complement system. Rapid pro-
liferation of macrophages might lead to adaptive immunity (T cell responses) activation
and tumour clearance, this explains why the protein MASP1 that regulates the com-
plement system [68] is under-expressed in breast cancer patients and over-expressed
in tumour-free samples. Bacteria products, such as staphylococcus aureus infection
activate the complement and coagulation cascades [94]. Staphylococcus bacteria is a
common cause for breast abscesses (an accumulation of pus and inflammation in breast
tissue) and is associated with development of rare kinds of breast cancer [45]. The bac-
teria can produce proteins that inhibit complement system activation, and it can express
super-antigens that prevent a normal immune response [45].
The odd-shared DEGs across tumour and tumour-free samples share pathways includ-
ing metabolic (hsa01100), cytokine-cytokine receptor interaction (hsa04060), focal ad-
hesion (hsa04510) and phosphatidylinositol 3’ -kinase(PI3K)-Akt signalling (hsa04151).
Cytokine-cytokine receptor interaction pathway stimulate responses through binding
to specific receptors. Proteins, such as Vascular endothelial growth factor D (FIGF)
and Thymic stromal lymphopoietin (TSLP) were found to be involved in the cytokine-
cytokine receptor pathway. Cancer cells require high metabolism, and pathways regu-
lating cell metabolism are often reprogrammed to sustain the rapid cell proliferation of
cancer cells [9].
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Discussion and conclusion
In our study, we developed a new non-linear ODE model to predict the role of cytokines
in tumour-immune cell dynamics. The numerical analysis in Chapter 3 emphasized
the role of cytokines in activating an immune response, and promoting tumour pro-
gression [12]. From the numerical analysis, TGF-β predominantly secreted by tumour
cells and Tregs was found to be crucial for tumour proliferation and progression. The
inhibiting effect of TGF-β, limited the effectiveness of type 1 immune response. The ab-
sence of TGF-β resulted in the immune cells growing without bound and this can result
in a series of serious dysfunctional organs [14]. We observed that tumour regression
occurred when (i) type 1 immune response was not inhibited by TGF-β and (ii) the in-
trinsic growth rate was decreased by 25% from its baseline value 0.502. The intrinsic
growth rate of tumour cells can be decreased by use of cancer therapies or changing
the local TME to favour pro-inflammatory cytokines and type 1 immune signals. The
persistence of type 2 immune response after type 1 signals were depleted on day 10 pro-
moted tumour progression, because of the rich anti-inflammatory cytokines available at
the tumour site. Our work complements the role Th2 and Th17 cells play in inhibiting
the proliferation of M1 macrophages, CTLs, NK and Th1 cells.
For an immune cell to be activated from a resting state, its gene expression has to be al-
tered. Thus we downloaded and analysed breast cancer RNA-Seq data from The cancer
Genome Atlas project. The goal for analysing gene expression data is to predict DEGs,
pathways and biological processes that can explain phenotypic differences across sam-
ples. Significance analysis of micro-arrays (SAM) approach was used to predict DEGs
across breast cancer and tumour-free samples. We predicted and selected 40 genes that
were differentially expressed and common between the two samples that might explain
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the phenotypic differences. These 40 genes were either over-expressed in tumour sam-
ples, but under-expressed in tumour-free samples or under-expressed in tumour sam-
ples, but over-expressed in tumour-free samples.
A hyper-geometric test was used to predict enriched biological processes and signifi-
cant pathways of the selected gene set. Enriched biological processes, such as ubiqui-
tin system, mitotic cytokinesis and chromosome condensation were over-represented in
the genes that were over-expressed in tumour samples. These enriched processes can
be used for future research of breast cancer progression and regulation of APCs. The
over-expressed genes in tumour samples were associated with pathways including cel-
lular senescence and protein digestion and absorption. These pathways can be used
for future research of breast cancer growth and proliferation. DEGs including MYBL2
and FOXM1 can be used as markers for cellular senescence pathway while COL10A1
and COL11A1 can be used as markers for protein digestion and absorption pathway.
The over-expressed genes in tumour-free samples were associated with pathways, such
as staphylococcus aureus infection and complement and coagulation cascades. These
pathways are involved in activating a normal immune response.
In future we will, (i) study the effect of TGF-β without the logistic proliferation terms
and with treatment, (ii) investigate the influence of tumour cells on dendritic cells that
favours the differentiation of M2 macrophages at the expense of M1 macrophages, (iii)
predict the overall survival rates of breast cancer patients with the identified enriched
pathways and biological processes and (iv) predict the suitability of the identified over-
expressed DEGs in tumour samples, enriched biological processes and significant path-
ways as target for breast cancer diagnosis, prognosis and treatment.
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